{"transactions":[{"id":1958913,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":111914,"kind":"organization","name":"Sumitomo Chemical Co., Ltd.","position":1,"cik":"0001798550","reported_name":"Sumitomo Chemical Co., Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111915,"kind":"organization","name":"Sumitomo Pharma Co., Ltd.","position":2,"cik":"0001446601","reported_name":"Sumitomo Pharma Co., Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":115694,"kind":"organization","name":"Sumitovant Biopharma Ltd.","position":3,"cik":"0001798244","reported_name":"Sumitovant Biopharma Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares","published_at":"2023-03-10T14:17:15.000Z","date":"2023-03-10","kind":"purchase","acquired":true,"shares":51599200,"price":27,"value":1393178400.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On March 10, 2023, Sumitovant Biopharma Ltd. (\"Sumitovant\") acquired all of the common shares of Myovant Sciences Ltd. (the \"Issuer\") not previously held by it pursuant to the terms of an Agreement and Plan of Merger, dated as of October 23, 2022 (the \"Merger Agreement\"), and a related Statutory Merger Agreement (the \"Statutory Merger Agreement\", and together with the Merger Agreement, the \"Merger Agreements\"), entered into by and among the Issuer, Sumitovant, Zeus Sciences Ltd., a wholly owned subsidiary of Sumitovant (\"Merger Sub\"), and other parties thereto."},{"field":"shares","element":"transactionShares","label":"F2","text":"(Continued from footnote 1) Pursuant to the Merger Agreements, Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Sumitovant (the \"Merger\"). At the effective time of the Merger (the \"Effective Time\"), each common share of the Issuer outstanding immediately prior to the Effective Time (other than certain excluded shares) automatically converted into the right to receive $27.00 in cash, without interest and less any applicable withholding taxes."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"On March 10, 2023, Sumitovant Biopharma Ltd. (\"Sumitovant\") acquired all of the common shares of Myovant Sciences Ltd. (the \"Issuer\") not previously held by it pursuant to the terms of an Agreement and Plan of Merger, dated as of October 23, 2022 (the \"Merger Agreement\"), and a related Statutory Merger Agreement (the \"Statutory Merger Agreement\", and together with the Merger Agreement, the \"Merger Agreements\"), entered into by and among the Issuer, Sumitovant, Zeus Sciences Ltd., a wholly owned subsidiary of Sumitovant (\"Merger Sub\"), and other parties thereto."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"(Continued from footnote 1) Pursuant to the Merger Agreements, Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Sumitovant (the \"Merger\"). At the effective time of the Merger (the \"Effective Time\"), each common share of the Issuer outstanding immediately prior to the Effective Time (other than certain excluded shares) automatically converted into the right to receive $27.00 in cash, without interest and less any applicable withholding taxes."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Sumitovant is a wholly-owned subsidiary of Sumitomo Pharma Co., Ltd. (\"Sumitomo Pharma\"), which is a 51.76% owned subsidiary of Sumitomo Chemical Co., Ltd. (\"Sumitomo Chemical\"). Sumitomo Pharma and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Pharma and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein."}],"balance_after":45798176,"source":{"system":"sec-edgar","filing":"0000899243-23-007864","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1798550/000089924323007864/doc4.xml","form_type":"4"}},{"id":1969274,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":111914,"kind":"organization","name":"Sumitomo Chemical Co., Ltd.","position":1,"cik":"0001798550","reported_name":"Sumitomo Chemical Co., Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111915,"kind":"organization","name":"Sumitomo Pharma Co., Ltd.","position":2,"cik":"0001446601","reported_name":"Sumitomo Pharma Co., Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":115694,"kind":"organization","name":"Sumitovant Biopharma Ltd.","position":3,"cik":"0001798244","reported_name":"Sumitovant Biopharma Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Option (Right to Acquire)","published_at":"2023-03-06T11:15:10.000Z","date":"2023-03-03","kind":"other","acquired":true,"shares":1,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"security","element":"securityTitle","label":"F3","text":"Contemporaneously with the Share Return, Roivant agreed to grant Sumitovant an option (the \"Option\") to purchase a number of Common Shares then owned by Roivant up to 4,243,005 Common Shares, at a price equal to $27.00 per Common Share. The Option may be exercised by Sumitovant at any time during the period beginning on March 3, 2023 and ending on March 30, 2023."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Contemporaneously with the Share Return, Roivant agreed to grant Sumitovant an option (the \"Option\") to purchase a number of Common Shares then owned by Roivant up to 4,243,005 Common Shares, at a price equal to $27.00 per Common Share. The Option may be exercised by Sumitovant at any time during the period beginning on March 3, 2023 and ending on March 30, 2023."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F3","text":"Contemporaneously with the Share Return, Roivant agreed to grant Sumitovant an option (the \"Option\") to purchase a number of Common Shares then owned by Roivant up to 4,243,005 Common Shares, at a price equal to $27.00 per Common Share. The Option may be exercised by Sumitovant at any time during the period beginning on March 3, 2023 and ending on March 30, 2023."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Sumitovant directly owns 45,798,176 Common Shares following the Share Return. Sumitovant is a wholly-owned subsidiary of Sumitomo Pharma, which is a 51.76% owned subsidiary of Sumitomo Chemical Co., Ltd. (\"Sumitomo Chemical\"). Sumitomo Pharma and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Pharma and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein."}],"balance_after":1,"derivative":{"exercise_price":27,"exercise_date":"2023-03-03","expiration_date":"2023-03-30","underlying":"Common Shares","underlying_shares":4243005},"source":{"system":"sec-edgar","filing":"0000899243-23-007110","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1798550/000089924323007110/doc4.xml","form_type":"4"}},{"id":1969273,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":111914,"kind":"organization","name":"Sumitomo Chemical Co., Ltd.","position":1,"cik":"0001798550","reported_name":"Sumitomo Chemical Co., Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111915,"kind":"organization","name":"Sumitomo Pharma Co., Ltd.","position":2,"cik":"0001446601","reported_name":"Sumitomo Pharma Co., Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":115694,"kind":"organization","name":"Sumitovant Biopharma Ltd.","position":3,"cik":"0001798244","reported_name":"Sumitovant Biopharma Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Shares","published_at":"2023-03-06T11:15:10.000Z","date":"2023-03-03","kind":"other","acquired":false,"shares":4243005,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On March 3, 2023, Sumitovant Biopharma Ltd. (\"Sumitovant\") voluntarily returned to Roivant Sciences Ltd., a Bermuda exempted company limited by shares (\"Roivant\"), for no consideration, 4,243,005  common shares, par value $0.000017727 per share (each, a \"Common Share\") of Myovant Sciences Ltd. (the \"Issuer\") subject to that certain Share Return Agreement, dated as of December 27, 2019, by and among Sumitovant, Roivant and Sumitomo Pharma Co., Ltd. (\"Sumitomo Pharma\") (the \"Share Return\").  In addition, Sumitovant, Sumitomo Pharma and Roivant agreed that, in the event that the Agreement and Plan of Merger, dated as of October 23, 2022 (as it may be amended from time to time in accordance with its terms, the \"Merger Agreement\"), by and among the Issuer, Sumitovant, Zeus Sciences Ltd. and, solely with respect to Article IX and Annex A of the Merger Agreement, Sumitomo Pharma, is terminated in accordance with its terms, Roivant will return such Common Shares to Sumitovant."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"On March 3, 2023, Sumitovant Biopharma Ltd. (\"Sumitovant\") voluntarily returned to Roivant Sciences Ltd., a Bermuda exempted company limited by shares (\"Roivant\"), for no consideration, 4,243,005  common shares, par value $0.000017727 per share (each, a \"Common Share\") of Myovant Sciences Ltd. (the \"Issuer\") subject to that certain Share Return Agreement, dated as of December 27, 2019, by and among Sumitovant, Roivant and Sumitomo Pharma Co., Ltd. (\"Sumitomo Pharma\") (the \"Share Return\").  In addition, Sumitovant, Sumitomo Pharma and Roivant agreed that, in the event that the Agreement and Plan of Merger, dated as of October 23, 2022 (as it may be amended from time to time in accordance with its terms, the \"Merger Agreement\"), by and among the Issuer, Sumitovant, Zeus Sciences Ltd. and, solely with respect to Article IX and Annex A of the Merger Agreement, Sumitomo Pharma, is terminated in accordance with its terms, Roivant will return such Common Shares to Sumitovant."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Sumitovant directly owns 45,798,176 Common Shares following the Share Return. Sumitovant is a wholly-owned subsidiary of Sumitomo Pharma, which is a 51.76% owned subsidiary of Sumitomo Chemical Co., Ltd. (\"Sumitomo Chemical\"). Sumitomo Pharma and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Pharma and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein."}],"balance_after":45798176,"source":{"system":"sec-edgar","filing":"0000899243-23-007110","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1798550/000089924323007110/doc4.xml","form_type":"4"}},{"id":2555841,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":111914,"kind":"organization","name":"Sumitomo Chemical Co., Ltd.","position":1,"cik":"0001798550","reported_name":"Sumitomo Chemical Co., Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111915,"kind":"organization","name":"Sumitomo Pharma Co., Ltd.","position":2,"cik":"0001446601","reported_name":"Dainippon Sumitomo Pharma Co Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":115694,"kind":"organization","name":"Sumitovant Biopharma Ltd.","position":3,"cik":"0001798244","reported_name":"Sumitovant Biopharma Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-09-30T21:00:20.000Z","date":"2021-09-28","kind":"purchase","acquired":true,"shares":20677,"price":22.8458,"value":472382.6066,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This acquisition of a total of 20,677 ordinary shares on the open market is pursuant to a Rule 10b5-1 Stock Trading Plan entered into by the Reporting Person on May 14, 2021 (the \"10b5-1 Trading Plan\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transaction was executed in multiple trades ranging from $22.54 to $23.51 per share. The price reported above reflects the weighted average purchase price.  The Reporting Person hereby undertakes to provide, upon request by the Commission Staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transactions were effected."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Sumitovant Biopharma Ltd. (\"Sumitovant\") directly owns a total of 50,041,181 shares of Common Stock following the acquisition on September 28, 2021. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd. (\"Sumitomo Dainippon\"), which is a 51.76% owned subsidiary of Sumitomo Chemical Co., Ltd. (\"Sumitomo Chemical\"). Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein."}],"balance_after":50041181,"source":{"system":"sec-edgar","filing":"0000899243-21-038387","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1798550/000089924321038387/doc4.xml","form_type":"4"}},{"id":2557760,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":111914,"kind":"organization","name":"Sumitomo Chemical Co., Ltd.","position":1,"cik":"0001798550","reported_name":"Sumitomo Chemical Co., Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111915,"kind":"organization","name":"Sumitomo Pharma Co., Ltd.","position":2,"cik":"0001446601","reported_name":"Dainippon Sumitomo Pharma Co Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":115694,"kind":"organization","name":"Sumitovant Biopharma Ltd.","position":3,"cik":"0001798244","reported_name":"Sumitovant Biopharma Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-09-28T21:00:19.000Z","date":"2021-09-27","kind":"purchase","acquired":true,"shares":2232,"price":24.8594,"value":55486.1808,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"This acquisition of a total of 48,000 ordinary shares on the open market is pursuant to the 10b5-1 Trading Plan."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The transaction was executed in multiple trades ranging from $24.76 to $24.95 per share. The price reported above reflects the weighted average purchase price.  The Reporting Person hereby undertakes to provide, upon request by the Commission Staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transactions were effected."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Sumitovant directly owns 50,020,504 shares of Common Stock following the acquisition on September 27, 2021. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon, which is a 51.76% owned subsidiary of Sumitomo Chemical. Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein."}],"balance_after":50020504,"source":{"system":"sec-edgar","filing":"0000899243-21-038083","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1798550/000089924321038083/doc4.xml","form_type":"4"}},{"id":2557759,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":111914,"kind":"organization","name":"Sumitomo Chemical Co., Ltd.","position":1,"cik":"0001798550","reported_name":"Sumitomo Chemical Co., Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111915,"kind":"organization","name":"Sumitomo Pharma Co., Ltd.","position":2,"cik":"0001446601","reported_name":"Dainippon Sumitomo Pharma Co Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":115694,"kind":"organization","name":"Sumitovant Biopharma Ltd.","position":3,"cik":"0001798244","reported_name":"Sumitovant Biopharma Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-09-28T21:00:19.000Z","date":"2021-09-27","kind":"purchase","acquired":true,"shares":45768,"price":24.1851,"value":1106903.6568,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"This acquisition of a total of 48,000 ordinary shares on the open market is pursuant to the 10b5-1 Trading Plan."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The transaction was executed in multiple trades ranging from $23.73 to $24.65 per share. The price reported above reflects the weighted average purchase price.  The Reporting Person hereby undertakes to provide, upon request by the Commission Staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transactions were effected."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Sumitovant directly owns 50,020,504 shares of Common Stock following the acquisition on September 27, 2021. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon, which is a 51.76% owned subsidiary of Sumitomo Chemical. Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein."}],"balance_after":50018272,"source":{"system":"sec-edgar","filing":"0000899243-21-038083","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1798550/000089924321038083/doc4.xml","form_type":"4"}},{"id":2557758,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":111914,"kind":"organization","name":"Sumitomo Chemical Co., Ltd.","position":1,"cik":"0001798550","reported_name":"Sumitomo Chemical Co., Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111915,"kind":"organization","name":"Sumitomo Pharma Co., Ltd.","position":2,"cik":"0001446601","reported_name":"Dainippon Sumitomo Pharma Co Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":115694,"kind":"organization","name":"Sumitovant Biopharma Ltd.","position":3,"cik":"0001798244","reported_name":"Sumitovant Biopharma Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-09-28T21:00:19.000Z","date":"2021-09-24","kind":"purchase","acquired":true,"shares":36000,"price":23.4041,"value":842547.6,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This acquisition of a total of 36,000 ordinary shares on the open market is pursuant to a Rule 10b5-1 Stock Trading Plan entered into by the Reporting Person on May 14, 2021 (the \"10b5-1 Trading Plan\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transaction was executed in multiple trades ranging from $23.00 to $23.68 per share. The price reported above reflects the weighted average purchase price.  The Reporting Person hereby undertakes to provide, upon request by the Commission Staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transactions were effected."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Sumitovant Biopharma Ltd. (\"Sumitovant\") directly owns a total of 49,972,504 shares of Common Stock following the acquisition on September 24, 2021. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd. (\"Sumitomo Dainippon\"), which is a 51.76% owned subsidiary of Sumitomo Chemical Co., Ltd. (\"Sumitomo Chemical\"). Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein."}],"balance_after":49972504,"source":{"system":"sec-edgar","filing":"0000899243-21-038083","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1798550/000089924321038083/doc4.xml","form_type":"4"}},{"id":2559926,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":111914,"kind":"organization","name":"Sumitomo Chemical Co., Ltd.","position":1,"cik":"0001798550","reported_name":"Sumitomo Chemical Co., Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111915,"kind":"organization","name":"Sumitomo Pharma Co., Ltd.","position":2,"cik":"0001446601","reported_name":"Dainippon Sumitomo Pharma Co Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":115694,"kind":"organization","name":"Sumitovant Biopharma Ltd.","position":3,"cik":"0001798244","reported_name":"Sumitovant Biopharma Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-09-24T21:00:15.000Z","date":"2021-09-23","kind":"purchase","acquired":true,"shares":5311,"price":23.4885,"value":124747.4235,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"This acquisition of a total of 54,778 ordinary shares on the open market is pursuant to the 10b5-1 Trading Plan."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The transaction was executed in multiple trades ranging from $23.42 to $23.50 per share. The price reported above reflects the weighted average purchase price.  The Reporting Person hereby undertakes to provide, upon request by the Commission Staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transactions were effected."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Sumitovant directly owns 49,936,504 shares of Common Stock following the acquisition on September 23, 2021. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon, which is a 51.76% owned subsidiary of Sumitomo Chemical. Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein."}],"balance_after":49936504,"source":{"system":"sec-edgar","filing":"0000899243-21-037631","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1798550/000089924321037631/doc4.xml","form_type":"4"}},{"id":2559925,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":111914,"kind":"organization","name":"Sumitomo Chemical Co., Ltd.","position":1,"cik":"0001798550","reported_name":"Sumitomo Chemical Co., Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111915,"kind":"organization","name":"Sumitomo Pharma Co., Ltd.","position":2,"cik":"0001446601","reported_name":"Dainippon Sumitomo Pharma Co Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":115694,"kind":"organization","name":"Sumitovant Biopharma Ltd.","position":3,"cik":"0001798244","reported_name":"Sumitovant Biopharma Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-09-24T21:00:15.000Z","date":"2021-09-23","kind":"purchase","acquired":true,"shares":49467,"price":23.0147,"value":1138468.1649,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"This acquisition of a total of 54,778 ordinary shares on the open market is pursuant to the 10b5-1 Trading Plan."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The transaction was executed in multiple trades ranging from $22.41 to $23.40 per share. The price reported above reflects the weighted average purchase price.  The Reporting Person hereby undertakes to provide, upon request by the Commission Staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transactions were effected."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Sumitovant directly owns 49,936,504 shares of Common Stock following the acquisition on September 23, 2021. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon, which is a 51.76% owned subsidiary of Sumitomo Chemical. Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein."}],"balance_after":49931193,"source":{"system":"sec-edgar","filing":"0000899243-21-037631","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1798550/000089924321037631/doc4.xml","form_type":"4"}},{"id":2559924,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":111914,"kind":"organization","name":"Sumitomo Chemical Co., Ltd.","position":1,"cik":"0001798550","reported_name":"Sumitomo Chemical Co., Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111915,"kind":"organization","name":"Sumitomo Pharma Co., Ltd.","position":2,"cik":"0001446601","reported_name":"Dainippon Sumitomo Pharma Co Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":115694,"kind":"organization","name":"Sumitovant Biopharma Ltd.","position":3,"cik":"0001798244","reported_name":"Sumitovant Biopharma Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-09-24T21:00:15.000Z","date":"2021-09-22","kind":"purchase","acquired":true,"shares":84018,"price":21.9597,"value":1845010.0746,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This acquisition of a total of 84,018 ordinary shares on the open market is pursuant to a Rule 10b5-1 Stock Trading Plan entered into by the Reporting Person on May 14, 2021 (the \"10b5-1 Trading Plan\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transaction was executed in multiple trades ranging from $21.54 to $22.48 per share. The price reported above reflects the weighted average purchase price.  The Reporting Person hereby undertakes to provide, upon request by the Commission Staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transactions were effected."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Sumitovant Biopharma Ltd. (\"Sumitovant\") directly owns a total of 49,881,726 shares of Common Stock following the acquisition on September 22, 2021. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd. (\"Sumitomo Dainippon\"), which is a 51.76% owned subsidiary of Sumitomo Chemical Co., Ltd. (\"Sumitomo Chemical\"). Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein."}],"balance_after":49881726,"source":{"system":"sec-edgar","filing":"0000899243-21-037631","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1798550/000089924321037631/doc4.xml","form_type":"4"}},{"id":2562123,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":111914,"kind":"organization","name":"Sumitomo Chemical Co., Ltd.","position":1,"cik":"0001798550","reported_name":"Sumitomo Chemical Co., Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111915,"kind":"organization","name":"Sumitomo Pharma Co., Ltd.","position":2,"cik":"0001446601","reported_name":"Dainippon Sumitomo Pharma Co Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":115694,"kind":"organization","name":"Sumitovant Biopharma Ltd.","position":3,"cik":"0001798244","reported_name":"Sumitovant Biopharma Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-09-22T21:00:13.000Z","date":"2021-09-21","kind":"purchase","acquired":true,"shares":43000,"price":22.4756,"value":966450.8,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"This acquisition of a total of 43,000 ordinary shares on the open market is pursuant to the 10b5-1 Trading Plan."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The transaction was executed in multiple trades ranging from $22.17 to $22.77 per share. The price reported above reflects the weighted average purchase price.  The Reporting Person hereby undertakes to provide, upon request by the Commission Staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transactions were effected."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Sumitovant directly owns 49,797,708 shares of Common Stock following the acquisition on September 21, 2021. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon, which is a 51.76% owned subsidiary of Sumitomo Chemical. Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein."}],"balance_after":49797708,"source":{"system":"sec-edgar","filing":"0000899243-21-037114","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1798550/000089924321037114/doc4.xml","form_type":"4"}},{"id":2562122,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":111914,"kind":"organization","name":"Sumitomo Chemical Co., Ltd.","position":1,"cik":"0001798550","reported_name":"Sumitomo Chemical Co., Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111915,"kind":"organization","name":"Sumitomo Pharma Co., Ltd.","position":2,"cik":"0001446601","reported_name":"Dainippon Sumitomo Pharma Co Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":115694,"kind":"organization","name":"Sumitovant Biopharma Ltd.","position":3,"cik":"0001798244","reported_name":"Sumitovant Biopharma Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-09-22T21:00:13.000Z","date":"2021-09-20","kind":"purchase","acquired":true,"shares":38273,"price":22.0957,"value":845668.7261,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This acquisition of a total of 38,273 ordinary shares on the open market is pursuant to a Rule 10b5-1 Stock Trading Plan entered into by the Reporting Person on May 14, 2021 (the \"10b5-1 Trading Plan\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transaction was executed in multiple trades ranging from $21.80 to $22.36 per share. The price reported above reflects the weighted average purchase price.  The Reporting Person hereby undertakes to provide, upon request by the Commission Staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transactions were effected."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Sumitovant Biopharma Ltd. (\"Sumitovant\") directly owns a total of 49,754,708 shares of Common Stock following the acquisition on September 20, 2021. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd. (\"Sumitomo Dainippon\"), which is a 51.76% owned subsidiary of Sumitomo Chemical Co., Ltd. (\"Sumitomo Chemical\"). Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein."}],"balance_after":49754708,"source":{"system":"sec-edgar","filing":"0000899243-21-037114","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1798550/000089924321037114/doc4.xml","form_type":"4"}},{"id":2564122,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":111914,"kind":"organization","name":"Sumitomo Chemical Co., Ltd.","position":1,"cik":"0001798550","reported_name":"Sumitomo Chemical Co., Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111915,"kind":"organization","name":"Sumitomo Pharma Co., Ltd.","position":2,"cik":"0001446601","reported_name":"Dainippon Sumitomo Pharma Co Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":115694,"kind":"organization","name":"Sumitovant Biopharma Ltd.","position":3,"cik":"0001798244","reported_name":"Sumitovant Biopharma Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-09-20T21:00:26.000Z","date":"2021-09-17","kind":"purchase","acquired":true,"shares":37913,"price":22.7918,"value":864105.5134,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"This acquisition of a total of 37,913 ordinary shares on the open market is pursuant to the 10b5-1 Trading Plan."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The transaction was executed in multiple trades ranging from $22.43 to $23.19 per share. The price reported above reflects the weighted average purchase price.  The Reporting Person hereby undertakes to provide, upon request by the Commission Staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transactions were effected."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Sumitovant directly owns 49,716,435 shares of Common Stock following the acquisition on September 17, 2021. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon, which is a 51.76% owned subsidiary of Sumitomo Chemical. Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein."}],"balance_after":49716435,"source":{"system":"sec-edgar","filing":"0000899243-21-036597","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1798550/000089924321036597/doc4.xml","form_type":"4"}},{"id":2564121,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":111914,"kind":"organization","name":"Sumitomo Chemical Co., Ltd.","position":1,"cik":"0001798550","reported_name":"Sumitomo Chemical Co., Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111915,"kind":"organization","name":"Sumitomo Pharma Co., Ltd.","position":2,"cik":"0001446601","reported_name":"Dainippon Sumitomo Pharma Co Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":115694,"kind":"organization","name":"Sumitovant Biopharma Ltd.","position":3,"cik":"0001798244","reported_name":"Sumitovant Biopharma Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-09-20T21:00:26.000Z","date":"2021-09-16","kind":"purchase","acquired":true,"shares":50000,"price":21.751,"value":1087550.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This acquisition of a total of 50,000 ordinary shares on the open market is pursuant to a Rule 10b5-1 Stock Trading Plan entered into by the Reporting Person on May 14, 2021 (the \"10b5-1 Trading Plan\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transaction was executed in multiple trades ranging from $21.24 to $22.19 per share. The price reported above reflects the weighted average purchase price.  The Reporting Person hereby undertakes to provide, upon request by the Commission Staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transactions were effected."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Sumitovant Biopharma Ltd. (\"Sumitovant\") directly owns a total of 49,678,522 shares of Common Stock following the acquisition on September 16, 2021. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd. (\"Sumitomo Dainippon\"), which is a 51.76% owned subsidiary of Sumitomo Chemical Co., Ltd. (\"Sumitomo Chemical\"). Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein."}],"balance_after":49678522,"source":{"system":"sec-edgar","filing":"0000899243-21-036597","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1798550/000089924321036597/doc4.xml","form_type":"4"}},{"id":2567823,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":111914,"kind":"organization","name":"Sumitomo Chemical Co., Ltd.","position":1,"cik":"0001798550","reported_name":"Sumitomo Chemical Co., Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111915,"kind":"organization","name":"Sumitomo Pharma Co., Ltd.","position":2,"cik":"0001446601","reported_name":"Dainippon Sumitomo Pharma Co Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":115694,"kind":"organization","name":"Sumitovant Biopharma Ltd.","position":3,"cik":"0001798244","reported_name":"Sumitovant Biopharma Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-09-16T21:00:29.000Z","date":"2021-09-15","kind":"purchase","acquired":true,"shares":89864,"price":21.9831,"value":1975489.2984,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F5","text":"This acquisition of a total of 89,864 ordinary shares on the open market is pursuant to the 10b5-1 Trading Plan."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The transaction was executed in multiple trades ranging from $21.45 to $22.39 per share. The price reported above reflects the weighted average purchase price.  The Reporting Person hereby undertakes to provide, upon request by the Commission Staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transactions were effected."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"Sumitovant directly owns 49,628,522 shares of Common Stock following the acquisition on September 15, 2021. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon, which is a 51.76% owned subsidiary of Sumitomo Chemical. Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein."}],"balance_after":49628522,"source":{"system":"sec-edgar","filing":"0000899243-21-036290","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1798550/000089924321036290/doc4.xml","form_type":"4"}},{"id":2567822,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":111914,"kind":"organization","name":"Sumitomo Chemical Co., Ltd.","position":1,"cik":"0001798550","reported_name":"Sumitomo Chemical Co., Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111915,"kind":"organization","name":"Sumitomo Pharma Co., Ltd.","position":2,"cik":"0001446601","reported_name":"Dainippon Sumitomo Pharma Co Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":115694,"kind":"organization","name":"Sumitovant Biopharma Ltd.","position":3,"cik":"0001798244","reported_name":"Sumitovant Biopharma Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-09-16T21:00:29.000Z","date":"2021-09-14","kind":"purchase","acquired":true,"shares":6172,"price":22.7555,"value":140446.946,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This acquisition of a total of 71,300 ordinary shares on the open market is pursuant to a Rule 10b5-1 Stock Trading Plan entered into by the Reporting Person on May 14, 2021 (the \"10b5-1 Trading Plan\")."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The transaction was executed in multiple trades ranging from $22.64 to $22.89 per share. The price reported above reflects the weighted average purchase price.  The Reporting Person hereby undertakes to provide, upon request by the Commission Staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transactions were effected."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Sumitovant Biopharma Ltd. (\"Sumitovant\") directly owns a total of 49,538,658 shares of Common Stock following the acquisition on September 14, 2021. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd. (\"Sumitomo Dainippon\"), which is a 51.76% owned subsidiary of Sumitomo Chemical Co., Ltd. (\"Sumitomo Chemical\"). Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein."}],"balance_after":49538658,"source":{"system":"sec-edgar","filing":"0000899243-21-036290","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1798550/000089924321036290/doc4.xml","form_type":"4"}},{"id":2567821,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":111914,"kind":"organization","name":"Sumitomo Chemical Co., Ltd.","position":1,"cik":"0001798550","reported_name":"Sumitomo Chemical Co., Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111915,"kind":"organization","name":"Sumitomo Pharma Co., Ltd.","position":2,"cik":"0001446601","reported_name":"Dainippon Sumitomo Pharma Co Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":115694,"kind":"organization","name":"Sumitovant Biopharma Ltd.","position":3,"cik":"0001798244","reported_name":"Sumitovant Biopharma Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-09-16T21:00:29.000Z","date":"2021-09-14","kind":"purchase","acquired":true,"shares":65128,"price":22.0372,"value":1435238.7616,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This acquisition of a total of 71,300 ordinary shares on the open market is pursuant to a Rule 10b5-1 Stock Trading Plan entered into by the Reporting Person on May 14, 2021 (the \"10b5-1 Trading Plan\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transaction was executed in multiple trades ranging from $21.55 to $22.48 per share. The price reported above reflects the weighted average purchase price.  The Reporting Person hereby undertakes to provide, upon request by the Commission Staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transactions were effected."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Sumitovant Biopharma Ltd. (\"Sumitovant\") directly owns a total of 49,538,658 shares of Common Stock following the acquisition on September 14, 2021. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd. (\"Sumitomo Dainippon\"), which is a 51.76% owned subsidiary of Sumitomo Chemical Co., Ltd. (\"Sumitomo Chemical\"). Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein."}],"balance_after":49532486,"source":{"system":"sec-edgar","filing":"0000899243-21-036290","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1798550/000089924321036290/doc4.xml","form_type":"4"}},{"id":2570962,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":111914,"kind":"organization","name":"Sumitomo Chemical Co., Ltd.","position":1,"cik":"0001798550","reported_name":"Sumitomo Chemical Co., Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111915,"kind":"organization","name":"Sumitomo Pharma Co., Ltd.","position":2,"cik":"0001446601","reported_name":"Dainippon Sumitomo Pharma Co Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":115694,"kind":"organization","name":"Sumitovant Biopharma Ltd.","position":3,"cik":"0001798244","reported_name":"Sumitovant Biopharma Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-09-14T21:00:26.000Z","date":"2021-09-13","kind":"purchase","acquired":true,"shares":30028,"price":23.9107,"value":717990.4996,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"This acquisition of a total of 83,178 ordinary shares on the open market is pursuant to the 10b5-1 Trading Plan."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The transaction was executed in multiple trades ranging from $23.74 to $24.44 per share. The price reported above reflects the weighted average purchase price.  The Reporting Person hereby undertakes to provide, upon request by the Commission Staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transactions were effected."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Sumitovant directly owns 49,467,358 shares of Common Stock following the acquisition on September 13, 2021. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon, which is a 51.76% owned subsidiary of Sumitomo Chemical. Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein."}],"balance_after":49467358,"source":{"system":"sec-edgar","filing":"0000899243-21-035821","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1798550/000089924321035821/doc4.xml","form_type":"4"}},{"id":2570961,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":111914,"kind":"organization","name":"Sumitomo Chemical Co., Ltd.","position":1,"cik":"0001798550","reported_name":"Sumitomo Chemical Co., Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111915,"kind":"organization","name":"Sumitomo Pharma Co., Ltd.","position":2,"cik":"0001446601","reported_name":"Dainippon Sumitomo Pharma Co Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":115694,"kind":"organization","name":"Sumitovant Biopharma Ltd.","position":3,"cik":"0001798244","reported_name":"Sumitovant Biopharma Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-09-14T21:00:26.000Z","date":"2021-09-13","kind":"purchase","acquired":true,"shares":53150,"price":23.0867,"value":1227058.105,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"This acquisition of a total of 83,178 ordinary shares on the open market is pursuant to the 10b5-1 Trading Plan."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The transaction was executed in multiple trades ranging from $22.74 to $23.73 per share. The price reported above reflects the weighted average purchase price.  The Reporting Person hereby undertakes to provide, upon request by the Commission Staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transactions were effected."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Sumitovant directly owns 49,467,358 shares of Common Stock following the acquisition on September 13, 2021. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon, which is a 51.76% owned subsidiary of Sumitomo Chemical. Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein."}],"balance_after":49437330,"source":{"system":"sec-edgar","filing":"0000899243-21-035821","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1798550/000089924321035821/doc4.xml","form_type":"4"}},{"id":2570960,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":111914,"kind":"organization","name":"Sumitomo Chemical Co., Ltd.","position":1,"cik":"0001798550","reported_name":"Sumitomo Chemical Co., Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111915,"kind":"organization","name":"Sumitomo Pharma Co., Ltd.","position":2,"cik":"0001446601","reported_name":"Dainippon Sumitomo Pharma Co Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":115694,"kind":"organization","name":"Sumitovant Biopharma Ltd.","position":3,"cik":"0001798244","reported_name":"Sumitovant Biopharma Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-09-14T21:00:26.000Z","date":"2021-09-10","kind":"purchase","acquired":true,"shares":30000,"price":25.113,"value":753390.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This acquisition of a total of 30,000 ordinary shares on the open market is pursuant to a Rule 10b5-1 Stock Trading Plan entered into by the Reporting Person on May 14, 2021 (the \"10b5-1 Trading Plan\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transaction was executed in multiple trades ranging from $24.70 to $25.44 per share. The price reported above reflects the weighted average purchase price.  The Reporting Person hereby undertakes to provide, upon request by the Commission Staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transactions were effected."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Sumitovant Biopharma Ltd. (\"Sumitovant\") directly owns a total of 49,384,180 shares of Common Stock following the acquisition on September 10, 2021. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd. (\"Sumitomo Dainippon\"), which is a 51.76% owned subsidiary of Sumitomo Chemical Co., Ltd. (\"Sumitomo Chemical\"). Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein."}],"balance_after":49384180,"source":{"system":"sec-edgar","filing":"0000899243-21-035821","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1798550/000089924321035821/doc4.xml","form_type":"4"}},{"id":2573334,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":111914,"kind":"organization","name":"Sumitomo Chemical Co., Ltd.","position":1,"cik":"0001798550","reported_name":"Sumitomo Chemical Co., Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111915,"kind":"organization","name":"Sumitomo Pharma Co., Ltd.","position":2,"cik":"0001446601","reported_name":"Dainippon Sumitomo Pharma Co Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":115694,"kind":"organization","name":"Sumitovant Biopharma Ltd.","position":3,"cik":"0001798244","reported_name":"Sumitovant Biopharma Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-09-10T21:00:22.000Z","date":"2021-09-09","kind":"purchase","acquired":true,"shares":37000,"price":25.5175,"value":944147.5,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"This acquisition of a total of 37,000 ordinary shares on the open market is pursuant to the 10b5-1 Trading Plan."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The transaction was executed in multiple trades ranging from $25.14 to $26.00 per share. The price reported above reflects the weighted average purchase price.  The Reporting Person hereby undertakes to provide, upon request by the Commission Staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transactions were effected."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Sumitovant directly owns 49,354,180 shares of Common Stock following the acquisition on September 9, 2021. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon, which is a 51.76% owned subsidiary of Sumitomo Chemical. Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein."}],"balance_after":49354180,"source":{"system":"sec-edgar","filing":"0000899243-21-035564","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1798550/000089924321035564/doc4.xml","form_type":"4"}},{"id":2573333,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":111914,"kind":"organization","name":"Sumitomo Chemical Co., Ltd.","position":1,"cik":"0001798550","reported_name":"Sumitomo Chemical Co., Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111915,"kind":"organization","name":"Sumitomo Pharma Co., Ltd.","position":2,"cik":"0001446601","reported_name":"Dainippon Sumitomo Pharma Co Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":115694,"kind":"organization","name":"Sumitovant Biopharma Ltd.","position":3,"cik":"0001798244","reported_name":"Sumitovant Biopharma Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-09-10T21:00:22.000Z","date":"2021-09-08","kind":"purchase","acquired":true,"shares":21902,"price":25.7357,"value":563663.3014,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This acquisition of a total of 21,902 ordinary shares on the open market is pursuant to a Rule 10b5-1 Stock Trading Plan entered into by the Reporting Person on May 14, 2021 (the \"10b5-1 Trading Plan\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transaction was executed in multiple trades ranging from $25.26 to $26.23 per share. The price reported above reflects the weighted average purchase price.  The Reporting Person hereby undertakes to provide, upon request by the Commission Staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transactions were effected."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Sumitovant Biopharma Ltd. (\"Sumitovant\") directly owns a total of 49,317,180 shares of Common Stock following the acquisition on September 8, 2021. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd. (\"Sumitomo Dainippon\"), which is a 51.76% owned subsidiary of Sumitomo Chemical Co., Ltd. (\"Sumitomo Chemical\"). Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein."}],"balance_after":49317180,"source":{"system":"sec-edgar","filing":"0000899243-21-035564","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1798550/000089924321035564/doc4.xml","form_type":"4"}},{"id":2575980,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":111914,"kind":"organization","name":"Sumitomo Chemical Co., Ltd.","position":1,"cik":"0001798550","reported_name":"Sumitomo Chemical Co., Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111915,"kind":"organization","name":"Sumitomo Pharma Co., Ltd.","position":2,"cik":"0001446601","reported_name":"Dainippon Sumitomo Pharma Co Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":115694,"kind":"organization","name":"Sumitovant Biopharma Ltd.","position":3,"cik":"0001798244","reported_name":"Sumitovant Biopharma Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-09-08T21:00:23.000Z","date":"2021-09-07","kind":"purchase","acquired":true,"shares":4913,"price":27.1218,"value":133249.4034,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F5","text":"This acquisition of a total of 33,200 ordinary shares on the open market is pursuant to the 10b5-1 Trading Plan."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The transaction was executed in multiple trades ranging from $26.81 to $27.35 per share. The price reported above reflects the weighted average purchase price.  The Reporting Person hereby undertakes to provide, upon request by the Commission Staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transactions were effected."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"Sumitovant directly owns 49,295,278 shares of Common Stock following the acquisition on September 7, 2021. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon, which is a 51.76% owned subsidiary of Sumitomo Chemical. Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein."}],"balance_after":49295278,"source":{"system":"sec-edgar","filing":"0000899243-21-035342","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1798550/000089924321035342/doc4.xml","form_type":"4"}},{"id":2575979,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":111914,"kind":"organization","name":"Sumitomo Chemical Co., Ltd.","position":1,"cik":"0001798550","reported_name":"Sumitomo Chemical Co., Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111915,"kind":"organization","name":"Sumitomo Pharma Co., Ltd.","position":2,"cik":"0001446601","reported_name":"Dainippon Sumitomo Pharma Co Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":115694,"kind":"organization","name":"Sumitovant Biopharma Ltd.","position":3,"cik":"0001798244","reported_name":"Sumitovant Biopharma Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-09-08T21:00:23.000Z","date":"2021-09-07","kind":"purchase","acquired":true,"shares":28287,"price":26.0784,"value":737679.7008,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F5","text":"This acquisition of a total of 33,200 ordinary shares on the open market is pursuant to the 10b5-1 Trading Plan."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The transaction was executed in multiple trades ranging from $25.79 to $26.76 per share. The price reported above reflects the weighted average purchase price.  The Reporting Person hereby undertakes to provide, upon request by the Commission Staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transactions were effected."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"Sumitovant directly owns 49,295,278 shares of Common Stock following the acquisition on September 7, 2021. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon, which is a 51.76% owned subsidiary of Sumitomo Chemical. Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein."}],"balance_after":49290365,"source":{"system":"sec-edgar","filing":"0000899243-21-035342","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1798550/000089924321035342/doc4.xml","form_type":"4"}},{"id":2575978,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":111914,"kind":"organization","name":"Sumitomo Chemical Co., Ltd.","position":1,"cik":"0001798550","reported_name":"Sumitomo Chemical Co., Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111915,"kind":"organization","name":"Sumitomo Pharma Co., Ltd.","position":2,"cik":"0001446601","reported_name":"Dainippon Sumitomo Pharma Co Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":115694,"kind":"organization","name":"Sumitovant Biopharma Ltd.","position":3,"cik":"0001798244","reported_name":"Sumitovant Biopharma Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-09-08T21:00:23.000Z","date":"2021-09-03","kind":"purchase","acquired":true,"shares":1378,"price":27.2931,"value":37609.8918,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This acquisition of a total of 31,200 ordinary shares on the open market is pursuant to a Rule 10b5-1 Stock Trading Plan entered into by the Reporting Person on May 14, 2021 (the \"10b5-1 Trading Plan\")."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The transaction was executed in multiple trades ranging from $27.25 to $27.32 per share. The price reported above reflects the weighted average purchase price.  The Reporting Person hereby undertakes to provide, upon request by the Commission Staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transactions were effected."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Sumitovant Biopharma Ltd. (\"Sumitovant\") directly owns a total of 49,262,078 shares of Common Stock following the acquisition on September 3, 2021. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd. (\"Sumitomo Dainippon\"), which is a 51.76% owned subsidiary of Sumitomo Chemical Co., Ltd. (\"Sumitomo Chemical\"). Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein."}],"balance_after":49262078,"source":{"system":"sec-edgar","filing":"0000899243-21-035342","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1798550/000089924321035342/doc4.xml","form_type":"4"}},{"id":2575977,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":111914,"kind":"organization","name":"Sumitomo Chemical Co., Ltd.","position":1,"cik":"0001798550","reported_name":"Sumitomo Chemical Co., Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111915,"kind":"organization","name":"Sumitomo Pharma Co., Ltd.","position":2,"cik":"0001446601","reported_name":"Dainippon Sumitomo Pharma Co Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":115694,"kind":"organization","name":"Sumitovant Biopharma Ltd.","position":3,"cik":"0001798244","reported_name":"Sumitovant Biopharma Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-09-08T21:00:23.000Z","date":"2021-09-03","kind":"purchase","acquired":true,"shares":29822,"price":26.7381,"value":797383.6182,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This acquisition of a total of 31,200 ordinary shares on the open market is pursuant to a Rule 10b5-1 Stock Trading Plan entered into by the Reporting Person on May 14, 2021 (the \"10b5-1 Trading Plan\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transaction was executed in multiple trades ranging from $26.19 to $27.18 per share. The price reported above reflects the weighted average purchase price.  The Reporting Person hereby undertakes to provide, upon request by the Commission Staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transactions were effected."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Sumitovant Biopharma Ltd. (\"Sumitovant\") directly owns a total of 49,262,078 shares of Common Stock following the acquisition on September 3, 2021. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd. (\"Sumitomo Dainippon\"), which is a 51.76% owned subsidiary of Sumitomo Chemical Co., Ltd. (\"Sumitomo Chemical\"). Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein."}],"balance_after":49260700,"source":{"system":"sec-edgar","filing":"0000899243-21-035342","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1798550/000089924321035342/doc4.xml","form_type":"4"}},{"id":2579517,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":111914,"kind":"organization","name":"Sumitomo Chemical Co., Ltd.","position":1,"cik":"0001798550","reported_name":"Sumitomo Chemical Co., Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111915,"kind":"organization","name":"Sumitomo Pharma Co., Ltd.","position":2,"cik":"0001446601","reported_name":"Dainippon Sumitomo Pharma Co Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":115694,"kind":"organization","name":"Sumitovant Biopharma Ltd.","position":3,"cik":"0001798244","reported_name":"Sumitovant Biopharma Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-09-03T21:00:40.000Z","date":"2021-09-02","kind":"purchase","acquired":true,"shares":5848,"price":26.9547,"value":157631.0856,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"This acquisition of a total of 63,102 ordinary shares on the open market is pursuant to the 10b5-1 Trading Plan."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The transaction was executed in multiple trades ranging from $26.91 to $27.00 per share. The price reported above reflects the weighted average purchase price.  The Reporting Person hereby undertakes to provide, upon request by the Commission Staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transactions were effected."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Sumitovant directly owns 49,230,878 shares of Common Stock following the acquisition on September 2, 2021. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon, which is a 51.76% owned subsidiary of Sumitomo Chemical. Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein."}],"balance_after":49230878,"source":{"system":"sec-edgar","filing":"0000899243-21-035135","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1798550/000089924321035135/doc4.xml","form_type":"4"}},{"id":2579516,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":111914,"kind":"organization","name":"Sumitomo Chemical Co., Ltd.","position":1,"cik":"0001798550","reported_name":"Sumitomo Chemical Co., Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111915,"kind":"organization","name":"Sumitomo Pharma Co., Ltd.","position":2,"cik":"0001446601","reported_name":"Dainippon Sumitomo Pharma Co Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":115694,"kind":"organization","name":"Sumitovant Biopharma Ltd.","position":3,"cik":"0001798244","reported_name":"Sumitovant Biopharma Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-09-03T21:00:40.000Z","date":"2021-09-02","kind":"purchase","acquired":true,"shares":35045,"price":26.4628,"value":927388.826,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"This acquisition of a total of 63,102 ordinary shares on the open market is pursuant to the 10b5-1 Trading Plan."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The transaction was executed in multiple trades ranging from $25.90 to $26.89 per share. The price reported above reflects the weighted average purchase price.  The Reporting Person hereby undertakes to provide, upon request by the Commission Staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transactions were effected."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Sumitovant directly owns 49,230,878 shares of Common Stock following the acquisition on September 2, 2021. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon, which is a 51.76% owned subsidiary of Sumitomo Chemical. Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein."}],"balance_after":49225030,"source":{"system":"sec-edgar","filing":"0000899243-21-035135","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1798550/000089924321035135/doc4.xml","form_type":"4"}},{"id":2579515,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":111914,"kind":"organization","name":"Sumitomo Chemical Co., Ltd.","position":1,"cik":"0001798550","reported_name":"Sumitomo Chemical Co., Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111915,"kind":"organization","name":"Sumitomo Pharma Co., Ltd.","position":2,"cik":"0001446601","reported_name":"Dainippon Sumitomo Pharma Co Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":115694,"kind":"organization","name":"Sumitovant Biopharma Ltd.","position":3,"cik":"0001798244","reported_name":"Sumitovant Biopharma Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-09-03T21:00:40.000Z","date":"2021-09-02","kind":"purchase","acquired":true,"shares":22209,"price":25.2543,"value":560872.7487,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"This acquisition of a total of 63,102 ordinary shares on the open market is pursuant to the 10b5-1 Trading Plan."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The transaction was executed in multiple trades ranging from $24.85 to $25.80 per share. The price reported above reflects the weighted average purchase price.  The Reporting Person hereby undertakes to provide, upon request by the Commission Staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transactions were effected."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Sumitovant directly owns 49,230,878 shares of Common Stock following the acquisition on September 2, 2021. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon, which is a 51.76% owned subsidiary of Sumitomo Chemical. Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein."}],"balance_after":49189985,"source":{"system":"sec-edgar","filing":"0000899243-21-035135","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1798550/000089924321035135/doc4.xml","form_type":"4"}},{"id":2579514,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":111914,"kind":"organization","name":"Sumitomo Chemical Co., Ltd.","position":1,"cik":"0001798550","reported_name":"Sumitomo Chemical Co., Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111915,"kind":"organization","name":"Sumitomo Pharma Co., Ltd.","position":2,"cik":"0001446601","reported_name":"Dainippon Sumitomo Pharma Co Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":115694,"kind":"organization","name":"Sumitovant Biopharma Ltd.","position":3,"cik":"0001798244","reported_name":"Sumitovant Biopharma Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-09-03T21:00:40.000Z","date":"2021-09-01","kind":"purchase","acquired":true,"shares":40000,"price":24.8257,"value":993028.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This acquisition of a total of 40,000 ordinary shares on the open market is pursuant to a Rule 10b5-1 Stock Trading Plan entered into by the Reporting Person on May 14, 2021 (the \"10b5-1 Trading Plan\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transaction was executed in multiple trades ranging from $24.33 to $24.99 per share. The price reported above reflects the weighted average purchase price.  The Reporting Person hereby undertakes to provide, upon request by the Commission Staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transactions were effected."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Sumitovant Biopharma Ltd. (\"Sumitovant\") directly owns a total of 49,167,776 shares of Common Stock following the acquisition on September 1, 2021. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd. (\"Sumitomo Dainippon\"), which is a 51.76% owned subsidiary of Sumitomo Chemical Co., Ltd. (\"Sumitomo Chemical\"). Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein."}],"balance_after":49167776,"source":{"system":"sec-edgar","filing":"0000899243-21-035135","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1798550/000089924321035135/doc4.xml","form_type":"4"}},{"id":2583745,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":111914,"kind":"organization","name":"Sumitomo Chemical Co., Ltd.","position":1,"cik":"0001798550","reported_name":"Sumitomo Chemical Co., Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111915,"kind":"organization","name":"Sumitomo Pharma Co., Ltd.","position":2,"cik":"0001446601","reported_name":"Dainippon Sumitomo Pharma Co Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":115694,"kind":"organization","name":"Sumitovant Biopharma Ltd.","position":3,"cik":"0001798244","reported_name":"Sumitovant Biopharma Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-09-01T21:00:21.000Z","date":"2021-08-31","kind":"purchase","acquired":true,"shares":39000,"price":24.2791,"value":946884.9,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"This acquisition of a total of 39,000 ordinary shares on the open market is pursuant to the 10b5-1 Trading Plan."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The transaction was executed in multiple trades ranging from $23.79 to $24.59 per share. The price reported above reflects the weighted average purchase price.  The Reporting Person hereby undertakes to provide, upon request by the Commission Staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transactions were effected."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Sumitovant directly owns 49,127,776 shares of Common Stock following the acquisition on August 31, 2021. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon, which is a 51.76% owned subsidiary of Sumitomo Chemical. Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein."}],"balance_after":49127776,"source":{"system":"sec-edgar","filing":"0000899243-21-034765","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1798550/000089924321034765/doc4.xml","form_type":"4"}},{"id":2583744,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":111914,"kind":"organization","name":"Sumitomo Chemical Co., Ltd.","position":1,"cik":"0001798550","reported_name":"Sumitomo Chemical Co., Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111915,"kind":"organization","name":"Sumitomo Pharma Co., Ltd.","position":2,"cik":"0001446601","reported_name":"Dainippon Sumitomo Pharma Co Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":115694,"kind":"organization","name":"Sumitovant Biopharma Ltd.","position":3,"cik":"0001798244","reported_name":"Sumitovant Biopharma Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-09-01T21:00:21.000Z","date":"2021-08-30","kind":"purchase","acquired":true,"shares":70000,"price":23.9157,"value":1674099.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This acquisition of a total of 70,000 ordinary shares on the open market is pursuant to a Rule 10b5-1 Stock Trading Plan entered into by the Reporting Person on May 14, 2021 (the \"10b5-1 Trading Plan\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transaction was executed in multiple trades ranging from $23.51 to $24.00 per share. The price reported above reflects the weighted average purchase price.  The Reporting Person hereby undertakes to provide, upon request by the Commission Staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transactions were effected."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Sumitovant Biopharma Ltd. (\"Sumitovant\") directly owns a total of 49,088,776 shares of Common Stock following the acquisition on August 30, 2021. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd. (\"Sumitomo Dainippon\"), which is a 51.76% owned subsidiary of Sumitomo Chemical Co., Ltd. (\"Sumitomo Chemical\"). Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein."}],"balance_after":49088776,"source":{"system":"sec-edgar","filing":"0000899243-21-034765","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1798550/000089924321034765/doc4.xml","form_type":"4"}},{"id":2586676,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":111914,"kind":"organization","name":"Sumitomo Chemical Co., Ltd.","position":1,"cik":"0001798550","reported_name":"Sumitomo Chemical Co., Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111915,"kind":"organization","name":"Sumitomo Pharma Co., Ltd.","position":2,"cik":"0001446601","reported_name":"Dainippon Sumitomo Pharma Co Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":115694,"kind":"organization","name":"Sumitovant Biopharma Ltd.","position":3,"cik":"0001798244","reported_name":"Sumitovant Biopharma Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-08-30T21:00:18.000Z","date":"2021-08-27","kind":"purchase","acquired":true,"shares":37038,"price":23.1722,"value":858251.9436,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"This acquisition of a total of 37,038 ordinary shares on the open market is pursuant to the 10b5-1 Trading Plan."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The transaction was executed in multiple trades ranging from $22.61 to $23.51 per share. The price reported above reflects the weighted average purchase price.  The Reporting Person hereby undertakes to provide, upon request by the Commission Staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transactions were effected."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Sumitovant directly owns 49,018,776  shares of Common Stock following the acquisition on August 27, 2021. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon, which is a 51.76% owned subsidiary of Sumitomo Chemical. Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein."}],"balance_after":49018776,"source":{"system":"sec-edgar","filing":"0000899243-21-034525","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1798550/000089924321034525/doc4.xml","form_type":"4"}},{"id":2586675,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":111914,"kind":"organization","name":"Sumitomo Chemical Co., Ltd.","position":1,"cik":"0001798550","reported_name":"Sumitomo Chemical Co., Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111915,"kind":"organization","name":"Sumitomo Pharma Co., Ltd.","position":2,"cik":"0001446601","reported_name":"Dainippon Sumitomo Pharma Co Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":115694,"kind":"organization","name":"Sumitovant Biopharma Ltd.","position":3,"cik":"0001798244","reported_name":"Sumitovant Biopharma Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-08-30T21:00:18.000Z","date":"2021-08-26","kind":"purchase","acquired":true,"shares":40000,"price":22.6728,"value":906912.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This acquisition of a total of 40,000 ordinary shares on the open market is pursuant to a Rule 10b5-1 Stock Trading Plan entered into by the Reporting Person on May 14, 2021 (the \"10b5-1 Trading Plan\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transaction was executed in multiple trades ranging from $22.39 to $23.06 per share. The price reported above reflects the weighted average purchase price.  The Reporting Person hereby undertakes to provide, upon request by the Commission Staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transactions were effected."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Sumitovant Biopharma Ltd. (\"Sumitovant\") directly owns a total of 48,981,738 shares of Common Stock following the acquisition on August 26, 2021. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd. (\"Sumitomo Dainippon\"), which is a 51.76% owned subsidiary of Sumitomo Chemical Co., Ltd. (\"Sumitomo Chemical\"). Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein."}],"balance_after":48981738,"source":{"system":"sec-edgar","filing":"0000899243-21-034525","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1798550/000089924321034525/doc4.xml","form_type":"4"}},{"id":2589618,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":111914,"kind":"organization","name":"Sumitomo Chemical Co., Ltd.","position":1,"cik":"0001798550","reported_name":"Sumitomo Chemical Co., Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111915,"kind":"organization","name":"Sumitomo Pharma Co., Ltd.","position":2,"cik":"0001446601","reported_name":"Dainippon Sumitomo Pharma Co Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":115694,"kind":"organization","name":"Sumitovant Biopharma Ltd.","position":3,"cik":"0001798244","reported_name":"Sumitovant Biopharma Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-08-26T21:00:55.000Z","date":"2021-08-25","kind":"purchase","acquired":true,"shares":28709,"price":22.4375,"value":644158.1875,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"This acquisition of a total of 28,709 ordinary shares on the open market is pursuant to the 10b5-1 Trading Plan."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The transaction was executed in multiple trades ranging from $22.00 to $22.55 per share. The price reported above reflects the weighted average purchase price.  The Reporting Person hereby undertakes to provide, upon request by the Commission Staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transactions were effected."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Sumitovant directly owns 48,941,738 shares of Common Stock following the acquisition on August 25, 2021. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon, which is a 51.76% owned subsidiary of Sumitomo Chemical. Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein."}],"balance_after":48941738,"source":{"system":"sec-edgar","filing":"0000899243-21-034281","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1798550/000089924321034281/doc4.xml","form_type":"4"}},{"id":2589617,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":111914,"kind":"organization","name":"Sumitomo Chemical Co., Ltd.","position":1,"cik":"0001798550","reported_name":"Sumitomo Chemical Co., Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111915,"kind":"organization","name":"Sumitomo Pharma Co., Ltd.","position":2,"cik":"0001446601","reported_name":"Dainippon Sumitomo Pharma Co Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":115694,"kind":"organization","name":"Sumitovant Biopharma Ltd.","position":3,"cik":"0001798244","reported_name":"Sumitovant Biopharma Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-08-26T21:00:55.000Z","date":"2021-08-24","kind":"purchase","acquired":true,"shares":34299,"price":22.37,"value":767268.63,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This acquisition of a total of 34,299 ordinary shares on the open market is pursuant to a Rule 10b5-1 Stock Trading Plan entered into by the Reporting Person on May 14, 2021 (the \"10b5-1 Trading Plan\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transaction was executed in multiple trades ranging from $22.10 to $22.51 per share. The price reported above reflects the weighted average purchase price.  The Reporting Person hereby undertakes to provide, upon request by the Commission Staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transactions were effected."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Sumitovant Biopharma Ltd. (\"Sumitovant\") directly owns a total of 48,913,029 shares of Common Stock following the acquisition on August 24, 2021. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd. (\"Sumitomo Dainippon\"), which is a 51.76% owned subsidiary of Sumitomo Chemical Co., Ltd. (\"Sumitomo Chemical\"). Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein."}],"balance_after":48913029,"source":{"system":"sec-edgar","filing":"0000899243-21-034281","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1798550/000089924321034281/doc4.xml","form_type":"4"}},{"id":2592444,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":111914,"kind":"organization","name":"Sumitomo Chemical Co., Ltd.","position":1,"cik":"0001798550","reported_name":"Sumitomo Chemical Co., Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111915,"kind":"organization","name":"Sumitomo Pharma Co., Ltd.","position":2,"cik":"0001446601","reported_name":"Dainippon Sumitomo Pharma Co Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":115694,"kind":"organization","name":"Sumitovant Biopharma Ltd.","position":3,"cik":"0001798244","reported_name":"Sumitovant Biopharma Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-08-24T21:00:57.000Z","date":"2021-08-23","kind":"purchase","acquired":true,"shares":30390,"price":22.4522,"value":682322.358,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"This acquisition of a total of 55,447 ordinary shares on the open market is pursuant to the 10b5-1 Trading Plan."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The transaction was executed in multiple trades ranging from $22.36 to $22.66 per share. The price reported above reflects the weighted average purchase price.  The Reporting Person hereby undertakes to provide, upon request by the Commission Staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transactions were effected."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Sumitovant directly owns 48,878,730 shares of Common Stock following the acquisition on August 23, 2021. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon, which is a 51.76% owned subsidiary of Sumitomo Chemical. Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein."}],"balance_after":48878730,"source":{"system":"sec-edgar","filing":"0000899243-21-034046","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1798550/000089924321034046/doc4.xml","form_type":"4"}},{"id":2592443,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":111914,"kind":"organization","name":"Sumitomo Chemical Co., Ltd.","position":1,"cik":"0001798550","reported_name":"Sumitomo Chemical Co., Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111915,"kind":"organization","name":"Sumitomo Pharma Co., Ltd.","position":2,"cik":"0001446601","reported_name":"Dainippon Sumitomo Pharma Co Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":115694,"kind":"organization","name":"Sumitovant Biopharma Ltd.","position":3,"cik":"0001798244","reported_name":"Sumitovant Biopharma Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-08-24T21:00:57.000Z","date":"2021-08-23","kind":"purchase","acquired":true,"shares":25057,"price":22.1261,"value":554413.6877,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"This acquisition of a total of 55,447 ordinary shares on the open market is pursuant to the 10b5-1 Trading Plan."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The transaction was executed in multiple trades ranging from $21.36 to $22.35 per share. The price reported above reflects the weighted average purchase price.  The Reporting Person hereby undertakes to provide, upon request by the Commission Staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transactions were effected."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Sumitovant directly owns 48,878,730 shares of Common Stock following the acquisition on August 23, 2021. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon, which is a 51.76% owned subsidiary of Sumitomo Chemical. Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein."}],"balance_after":48848340,"source":{"system":"sec-edgar","filing":"0000899243-21-034046","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1798550/000089924321034046/doc4.xml","form_type":"4"}},{"id":2592442,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":111914,"kind":"organization","name":"Sumitomo Chemical Co., Ltd.","position":1,"cik":"0001798550","reported_name":"Sumitomo Chemical Co., Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111915,"kind":"organization","name":"Sumitomo Pharma Co., Ltd.","position":2,"cik":"0001446601","reported_name":"Dainippon Sumitomo Pharma Co Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":115694,"kind":"organization","name":"Sumitovant Biopharma Ltd.","position":3,"cik":"0001798244","reported_name":"Sumitovant Biopharma Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-08-24T21:00:57.000Z","date":"2021-08-20","kind":"purchase","acquired":true,"shares":46478,"price":20.8602,"value":969540.3756,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This acquisition of a total of 46,478 ordinary shares on the open market is pursuant to a Rule 10b5-1 Stock Trading Plan entered into by the Reporting Person on May 14, 2021 (the \"10b5-1 Trading Plan\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transaction was executed in multiple trades ranging from $20.32 to $21.27 per share. The price reported above reflects the weighted average purchase price.  The Reporting Person hereby undertakes to provide, upon request by the Commission Staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transactions were effected."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Sumitovant Biopharma Ltd. (\"Sumitovant\") directly owns a total of 48,823,283 shares of Common Stock following the acquisition on August 20, 2021. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd. (\"Sumitomo Dainippon\"), which is a 51.76% owned subsidiary of Sumitomo Chemical Co., Ltd. (\"Sumitomo Chemical\"). Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein."}],"balance_after":48823283,"source":{"system":"sec-edgar","filing":"0000899243-21-034046","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1798550/000089924321034046/doc4.xml","form_type":"4"}},{"id":2595009,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":111914,"kind":"organization","name":"Sumitomo Chemical Co., Ltd.","position":1,"cik":"0001798550","reported_name":"Sumitomo Chemical Co., Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111915,"kind":"organization","name":"Sumitomo Pharma Co., Ltd.","position":2,"cik":"0001446601","reported_name":"Dainippon Sumitomo Pharma Co Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":115694,"kind":"organization","name":"Sumitovant Biopharma Ltd.","position":3,"cik":"0001798244","reported_name":"Sumitovant Biopharma Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-08-20T21:00:32.000Z","date":"2021-08-19","kind":"purchase","acquired":true,"shares":46792,"price":21.5084,"value":1006421.0528,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"This acquisition of a total of 46,792 ordinary shares on the open market is pursuant to the 10b5-1 Trading Plan."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The transaction was executed in multiple trades ranging from $21.13 to $21.87 per share. The price reported above reflects the weighted average purchase price.  The Reporting Person hereby undertakes to provide, upon request by the Commission Staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transactions were effected."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Sumitovant directly owns 48,776,805 shares of Common Stock following the acquisition on August 19, 2021. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon, which is a 51.76% owned subsidiary of Sumitomo Chemical. Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein."}],"balance_after":48776805,"source":{"system":"sec-edgar","filing":"0000899243-21-033840","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1798550/000089924321033840/doc4.xml","form_type":"4"}},{"id":2595008,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":111914,"kind":"organization","name":"Sumitomo Chemical Co., Ltd.","position":1,"cik":"0001798550","reported_name":"Sumitomo Chemical Co., Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111915,"kind":"organization","name":"Sumitomo Pharma Co., Ltd.","position":2,"cik":"0001446601","reported_name":"Dainippon Sumitomo Pharma Co Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":115694,"kind":"organization","name":"Sumitovant Biopharma Ltd.","position":3,"cik":"0001798244","reported_name":"Sumitovant Biopharma Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-08-20T21:00:32.000Z","date":"2021-08-18","kind":"purchase","acquired":true,"shares":17116,"price":21.4473,"value":367091.9868,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This acquisition of a total of 17,116 ordinary shares on the open market is pursuant to a Rule 10b5-1 Stock Trading Plan entered into by the Reporting Person on May 14, 2021 (the \"10b5-1 Trading Plan\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transaction was executed in multiple trades ranging from $21.06 to $21.72 per share. The price reported above reflects the weighted average purchase price.  The Reporting Person hereby undertakes to provide, upon request by the Commission Staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transactions were effected."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Sumitovant Biopharma Ltd. (\"Sumitovant\") directly owns a total of 48,730,013 shares of Common Stock following the acquisition on August 18, 2021. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd. (\"Sumitomo Dainippon\"), which is a 51.76% owned subsidiary of Sumitomo Chemical Co., Ltd. (\"Sumitomo Chemical\"). Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein."}],"balance_after":48730013,"source":{"system":"sec-edgar","filing":"0000899243-21-033840","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1798550/000089924321033840/doc4.xml","form_type":"4"}},{"id":2598096,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":111914,"kind":"organization","name":"Sumitomo Chemical Co., Ltd.","position":1,"cik":"0001798550","reported_name":"Sumitomo Chemical Co., Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111915,"kind":"organization","name":"Sumitomo Pharma Co., Ltd.","position":2,"cik":"0001446601","reported_name":"Dainippon Sumitomo Pharma Co Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":115694,"kind":"organization","name":"Sumitovant Biopharma Ltd.","position":3,"cik":"0001798244","reported_name":"Sumitovant Biopharma Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-08-18T21:05:54.000Z","date":"2021-08-17","kind":"purchase","acquired":true,"shares":23549,"price":20.8947,"value":492049.2903,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F5","text":"This acquisition of a total of 23,549 ordinary shares on the open market is pursuant to the 10b5-1 Trading Plan."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The transaction was executed in multiple trades ranging from $20.46 to $21.15 per share. The price reported above reflects the weighted average purchase price.  The Reporting Person hereby undertakes to provide, upon request by the Commission Staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transactions were effected."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"Sumitovant directly owns 48,712,897 shares of Common Stock following the acquisition on August 17, 2021. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon, which is a 51.76 % owned subsidiary of Sumitomo Chemical. Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein."}],"balance_after":48712897,"source":{"system":"sec-edgar","filing":"0000899243-21-033476","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1798550/000089924321033476/doc4.xml","form_type":"4"}},{"id":2598095,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":111914,"kind":"organization","name":"Sumitomo Chemical Co., Ltd.","position":1,"cik":"0001798550","reported_name":"Sumitomo Chemical Co., Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111915,"kind":"organization","name":"Sumitomo Pharma Co., Ltd.","position":2,"cik":"0001446601","reported_name":"Dainippon Sumitomo Pharma Co Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":115694,"kind":"organization","name":"Sumitovant Biopharma Ltd.","position":3,"cik":"0001798244","reported_name":"Sumitovant Biopharma Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-08-18T21:05:54.000Z","date":"2021-08-16","kind":"purchase","acquired":true,"shares":5382,"price":21.9416,"value":118089.6912,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This acquisition of a total of 48,167 ordinary shares on the open market is pursuant to a Rule 10b5-1 Stock Trading Plan entered into by the Reporting Person on May 14, 2021 (the \"10b5-1 Trading Plan\")."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The transaction was executed in multiple trades ranging from $21.84 to $22.08 per share. The price reported above reflects the weighted average purchase price.  The Reporting Person herereby undertakes to provide, upon request by the Commission Staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transactions were effected."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Sumitovant Biopharma Ltd. (\"Sumitovant\") directly owns a total of 48,689,348 shares of Common Stock following the acquisition on August 16, 2021. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd. (\"Sumitomo Dainippon\"), which is a 51.76 % owned subsidiary of Sumitomo Chemical Co., Ltd. (\"Sumitomo Chemical\"). Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein."}],"balance_after":48689348,"source":{"system":"sec-edgar","filing":"0000899243-21-033476","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1798550/000089924321033476/doc4.xml","form_type":"4"}},{"id":2598094,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":111914,"kind":"organization","name":"Sumitomo Chemical Co., Ltd.","position":1,"cik":"0001798550","reported_name":"Sumitomo Chemical Co., Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111915,"kind":"organization","name":"Sumitomo Pharma Co., Ltd.","position":2,"cik":"0001446601","reported_name":"Dainippon Sumitomo Pharma Co Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":115694,"kind":"organization","name":"Sumitovant Biopharma Ltd.","position":3,"cik":"0001798244","reported_name":"Sumitovant Biopharma Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-08-18T21:05:54.000Z","date":"2021-08-16","kind":"purchase","acquired":true,"shares":42785,"price":21.2938,"value":911055.233,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This acquisition of a total of 48,167 ordinary shares on the open market is pursuant to a Rule 10b5-1 Stock Trading Plan entered into by the Reporting Person on May 14, 2021 (the \"10b5-1 Trading Plan\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transaction was executed in multiple trades ranging from $20.83 to $21.82 per share. The price reported above reflects the weighted average purchase price.  The Reporting Person hereby undertakes to provide, upon request by the Commission Staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transactions were effected."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Sumitovant Biopharma Ltd. (\"Sumitovant\") directly owns a total of 48,689,348 shares of Common Stock following the acquisition on August 16, 2021. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd. (\"Sumitomo Dainippon\"), which is a 51.76 % owned subsidiary of Sumitomo Chemical Co., Ltd. (\"Sumitomo Chemical\"). Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein."}],"balance_after":48683966,"source":{"system":"sec-edgar","filing":"0000899243-21-033476","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1798550/000089924321033476/doc4.xml","form_type":"4"}},{"id":3139344,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":111914,"kind":"organization","name":"Sumitomo Chemical Co., Ltd.","position":1,"cik":"0001798550","reported_name":"Sumitomo Chemical Co., Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111915,"kind":"organization","name":"Sumitomo Pharma Co., Ltd.","position":2,"cik":"0001446601","reported_name":"Dainippon Sumitomo Pharma Co Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":115694,"kind":"organization","name":"Sumitovant Biopharma Ltd.","position":3,"cik":"0001798244","reported_name":"Sumitovant Biopharma Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-05-21T17:25:07.000Z","date":"2020-05-20","kind":"purchase","acquired":true,"shares":37897,"price":12.5831,"value":476861.7407,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"This acquisition of a total of 37,897 ordinary shares on the open market is pursuant to the 10b5-1 Trading Plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in column 4 is the average stock price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Sumitovant directly owns 48,641,181 shares of Common Stock. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon, which is a 51.76% owned subsidiary of Sumitomo Chemical. Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein."}],"balance_after":48641181,"source":{"system":"sec-edgar","filing":"0000899243-20-013825","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1798550/000089924320013825/doc4.xml","form_type":"4"}},{"id":3139343,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":111914,"kind":"organization","name":"Sumitomo Chemical Co., Ltd.","position":1,"cik":"0001798550","reported_name":"Sumitomo Chemical Co., Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111915,"kind":"organization","name":"Sumitomo Pharma Co., Ltd.","position":2,"cik":"0001446601","reported_name":"Dainippon Sumitomo Pharma Co Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":115694,"kind":"organization","name":"Sumitovant Biopharma Ltd.","position":3,"cik":"0001798244","reported_name":"Sumitovant Biopharma Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-05-21T17:25:07.000Z","date":"2020-05-19","kind":"purchase","acquired":true,"shares":50000,"price":12.101,"value":605050.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This acquisition of a total of 50,000 ordinary shares on the open market is pursuant to a Rule 10b5-1 Stock Trading Plan entered into by the Reporting Person on March 13, 2020 (the \"10b5-1 Trading Plan\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in column 4 is the average stock price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Sumitovant Biopharma Ltd. (\"Sumitovant\") directly owns 48,603,284 shares of Common Stock. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd. (\"Sumitomo Dainippon\"), which is a 51.76% owned subsidiary of Sumitomo Chemical Co., Ltd. (\"Sumitomo Chemical\"). Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein."}],"balance_after":48603284,"source":{"system":"sec-edgar","filing":"0000899243-20-013825","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1798550/000089924320013825/doc4.xml","form_type":"4"}},{"id":3143082,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":111914,"kind":"organization","name":"Sumitomo Chemical Co., Ltd.","position":1,"cik":"0001798550","reported_name":"Sumitomo Chemical Co., Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111915,"kind":"organization","name":"Sumitomo Pharma Co., Ltd.","position":2,"cik":"0001446601","reported_name":"Dainippon Sumitomo Pharma Co Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":115694,"kind":"organization","name":"Sumitovant Biopharma Ltd.","position":3,"cik":"0001798244","reported_name":"Sumitovant Biopharma Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-05-19T19:13:26.000Z","date":"2020-05-18","kind":"purchase","acquired":true,"shares":35000,"price":12.3607,"value":432624.5,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"This acquisition of a total of 35,000 ordinary shares on the open market is pursuant to the 10b5-1 Trading Plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in column 4 is the average stock price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Sumitovant directly owns 48,553,284 shares of Common Stock. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon, which is a 51.76% owned subsidiary of Sumitomo Chemical. Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein."}],"balance_after":48553284,"source":{"system":"sec-edgar","filing":"0000899243-20-013546","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1798550/000089924320013546/doc4.xml","form_type":"4"}},{"id":3143081,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":111914,"kind":"organization","name":"Sumitomo Chemical Co., Ltd.","position":1,"cik":"0001798550","reported_name":"Sumitomo Chemical Co., Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111915,"kind":"organization","name":"Sumitomo Pharma Co., Ltd.","position":2,"cik":"0001446601","reported_name":"Dainippon Sumitomo Pharma Co Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":115694,"kind":"organization","name":"Sumitovant Biopharma Ltd.","position":3,"cik":"0001798244","reported_name":"Sumitovant Biopharma Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-05-19T19:13:26.000Z","date":"2020-05-15","kind":"purchase","acquired":true,"shares":49812,"price":12.1249,"value":603965.5188,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This acquisition of a total of 49,812 ordinary shares on the open market is pursuant to a Rule 10b5-1 Stock Trading Plan entered into by the Reporting Person on March 13, 2020 (the \"10b5-1 Trading Plan\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in column 4 is the average stock price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Sumitovant Biopharma Ltd. (\"Sumitovant\") directly owns 48,518,284 shares of Common Stock. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd. (\"Sumitomo Dainippon\"), which is a 51.76% owned subsidiary of Sumitomo Chemical Co., Ltd. (\"Sumitomo Chemical\"). Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein."}],"balance_after":48518284,"source":{"system":"sec-edgar","filing":"0000899243-20-013546","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1798550/000089924320013546/doc4.xml","form_type":"4"}},{"id":3147459,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":111914,"kind":"organization","name":"Sumitomo Chemical Co., Ltd.","position":1,"cik":"0001798550","reported_name":"Sumitomo Chemical Co., Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111915,"kind":"organization","name":"Sumitomo Pharma Co., Ltd.","position":2,"cik":"0001446601","reported_name":"Dainippon Sumitomo Pharma Co Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":115694,"kind":"organization","name":"Sumitovant Biopharma Ltd.","position":3,"cik":"0001798244","reported_name":"Sumitovant Biopharma Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-05-15T19:28:09.000Z","date":"2020-05-14","kind":"purchase","acquired":true,"shares":50000,"price":12.0152,"value":600760.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"This acquisition of a total of 50,000 ordinary shares on the open market is pursuant to the 10b5-1 Trading Plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in column 4 is the average stock price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Sumitovant directly owns 48,468,472 shares of Common Stock. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon, which is a 51.76% owned subsidiary of Sumitomo Chemical. Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein."}],"balance_after":48468472,"source":{"system":"sec-edgar","filing":"0000899243-20-013205","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1798550/000089924320013205/doc4.xml","form_type":"4"}},{"id":3147458,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":111914,"kind":"organization","name":"Sumitomo Chemical Co., Ltd.","position":1,"cik":"0001798550","reported_name":"Sumitomo Chemical Co., Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111915,"kind":"organization","name":"Sumitomo Pharma Co., Ltd.","position":2,"cik":"0001446601","reported_name":"Dainippon Sumitomo Pharma Co Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":115694,"kind":"organization","name":"Sumitovant Biopharma Ltd.","position":3,"cik":"0001798244","reported_name":"Sumitovant Biopharma Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-05-15T19:28:09.000Z","date":"2020-05-13","kind":"purchase","acquired":true,"shares":41331,"price":12.3791,"value":511640.5821,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This acquisition of a total of 41,331 ordinary shares on the open market is pursuant to a Rule 10b5-1 Stock Trading Plan entered into by the Reporting Person on March 13, 2020 (the \"10b5-1 Trading Plan\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in column 4 is the average stock price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Sumitovant Biopharma Ltd. (\"Sumitovant\") directly owns 48,418,472 shares of Common Stock. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd. (\"Sumitomo Dainippon\"), which is a 51.76% owned subsidiary of Sumitomo Chemical Co., Ltd. (\"Sumitomo Chemical\"). Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein."}],"balance_after":48418472,"source":{"system":"sec-edgar","filing":"0000899243-20-013205","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1798550/000089924320013205/doc4.xml","form_type":"4"}},{"id":3151109,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":111914,"kind":"organization","name":"Sumitomo Chemical Co., Ltd.","position":1,"cik":"0001798550","reported_name":"Sumitomo Chemical Co., Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111915,"kind":"organization","name":"Sumitomo Pharma Co., Ltd.","position":2,"cik":"0001446601","reported_name":"Dainippon Sumitomo Pharma Co Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":115694,"kind":"organization","name":"Sumitovant Biopharma Ltd.","position":3,"cik":"0001798244","reported_name":"Sumitovant Biopharma Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-05-13T22:50:53.000Z","date":"2020-05-12","kind":"purchase","acquired":true,"shares":24448,"price":13.5146,"value":330404.9408,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"This acquisition of a total of 24,448 ordinary shares on the open market is pursuant to the 10b5-1 Trading Plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in column 4 is the average stock price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Sumitovant directly owns 48,377,141 shares of Common Stock. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon, which is a 51.76% owned subsidiary of Sumitomo Chemical. Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein."}],"balance_after":48377141,"source":{"system":"sec-edgar","filing":"0000899243-20-013027","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1798550/000089924320013027/doc4.xml","form_type":"4"}},{"id":3151108,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":111914,"kind":"organization","name":"Sumitomo Chemical Co., Ltd.","position":1,"cik":"0001798550","reported_name":"Sumitomo Chemical Co., Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111915,"kind":"organization","name":"Sumitomo Pharma Co., Ltd.","position":2,"cik":"0001446601","reported_name":"Dainippon Sumitomo Pharma Co Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":115694,"kind":"organization","name":"Sumitovant Biopharma Ltd.","position":3,"cik":"0001798244","reported_name":"Sumitovant Biopharma Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-05-13T22:50:53.000Z","date":"2020-05-11","kind":"purchase","acquired":true,"shares":35000,"price":12.7824,"value":447384.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This acquisition of a total of 35,000 ordinary shares on the open market is pursuant to a Rule 10b5-1 Stock Trading Plan entered into by the Reporting Person on March 13, 2020 (the \"10b5-1 Trading Plan\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in column 4 is the average stock price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Sumitovant Biopharma Ltd. (\"Sumitovant\") directly owns 48,352,693 shares of Common Stock. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd. (\"Sumitomo Dainippon\"), which is a 51.76% owned subsidiary of Sumitomo Chemical Co., Ltd. (\"Sumitomo Chemical\"). Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein."}],"balance_after":48352693,"source":{"system":"sec-edgar","filing":"0000899243-20-013027","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1798550/000089924320013027/doc4.xml","form_type":"4"}},{"id":3154733,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":111914,"kind":"organization","name":"Sumitomo Chemical Co., Ltd.","position":1,"cik":"0001798550","reported_name":"Sumitomo Chemical Co., Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111915,"kind":"organization","name":"Sumitomo Pharma Co., Ltd.","position":2,"cik":"0001446601","reported_name":"Dainippon Sumitomo Pharma Co Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":115694,"kind":"organization","name":"Sumitovant Biopharma Ltd.","position":3,"cik":"0001798244","reported_name":"Sumitovant Biopharma Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-05-11T20:07:46.000Z","date":"2020-05-06","kind":"purchase","acquired":true,"shares":50000,"price":12.2415,"value":612075.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"On May 7, 2020, the Reporting Persons filed a Form 4 disclosing the acquisition of 50,000 shares of Common Stock at an average stock price of $11.6893 (the \"First Acquisition\") and 50,000 shares of Common Stock at an average stock price of $12.2415 (the \"Second Acquisition\"). The transaction date reported in Box 2 for both the First Acquisition and the Second Acquisition was May 5, 2020. The transaction date for the Second Acquisition was incorrectly reported and should have been reported as May 6, 2020."},{"field":"shares","element":"transactionShares","label":"F2","text":"This acquisition of a total of 50,000 ordinary shares on the open market is pursuant to a Rule 10b5-1 Stock Trading Plan entered into by the Reporting Person on March 13, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in column 4 is the average stock price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Sumitovant Biopharma Ltd. (\"Sumitovant\") directly owns 48,247,693 shares of Common Stock. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd. (\"Sumitomo Dainippon\"), which is a 51.76% owned subsidiary of Sumitomo Chemical Co., Ltd. (\"Sumitomo Chemical\"). Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein."}],"balance_after":48247693,"source":{"system":"sec-edgar","filing":"0000899243-20-012574","document":"doc4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1798550/000089924320012574/doc4a.xml","form_type":"4/A","original_submission_date":"2020-05-07"}},{"id":3154732,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":111914,"kind":"organization","name":"Sumitomo Chemical Co., Ltd.","position":1,"cik":"0001798550","reported_name":"Sumitomo Chemical Co., Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111915,"kind":"organization","name":"Sumitomo Pharma Co., Ltd.","position":2,"cik":"0001446601","reported_name":"Dainippon Sumitomo Pharma Co Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":115694,"kind":"organization","name":"Sumitovant Biopharma Ltd.","position":3,"cik":"0001798244","reported_name":"Sumitovant Biopharma Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-05-11T20:01:15.000Z","date":"2020-05-08","kind":"purchase","acquired":true,"shares":35000,"price":12.8307,"value":449074.5,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"This acquisition of a total of 35,000 ordinary shares on the open market is pursuant to the 10b5-1 Trading Plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in column 4 is the average stock price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Sumitovant directly owns 48,317,693 shares of Common Stock. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon, which is a 51.76% owned subsidiary of Sumitomo Chemical. Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein."}],"balance_after":48317693,"source":{"system":"sec-edgar","filing":"0000899243-20-012570","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1798550/000089924320012570/doc4.xml","form_type":"4"}},{"id":3154731,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":111914,"kind":"organization","name":"Sumitomo Chemical Co., Ltd.","position":1,"cik":"0001798550","reported_name":"Sumitomo Chemical Co., Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111915,"kind":"organization","name":"Sumitomo Pharma Co., Ltd.","position":2,"cik":"0001446601","reported_name":"Dainippon Sumitomo Pharma Co Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":115694,"kind":"organization","name":"Sumitovant Biopharma Ltd.","position":3,"cik":"0001798244","reported_name":"Sumitovant Biopharma Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-05-11T20:01:15.000Z","date":"2020-05-07","kind":"purchase","acquired":true,"shares":35000,"price":12.6325,"value":442137.5,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This acquisition of a total of 35,000 ordinary shares on the open market is pursuant to a Rule 10b5-1 Stock Trading Plan entered into by the Reporting Person on March 13, 2020 (the \"10b5-1 Trading Plan\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in column 4 is the average stock price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Sumitovant Biopharma Ltd. (\"Sumitovant\") directly owns 48,282,693 shares of Common Stock. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd. (\"Sumitomo Dainippon\"), which is a 51.76% owned subsidiary of Sumitomo Chemical Co., Ltd. (\"Sumitomo Chemical\"). Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein."}],"balance_after":48282693,"source":{"system":"sec-edgar","filing":"0000899243-20-012570","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1798550/000089924320012570/doc4.xml","form_type":"4"}},{"id":3158216,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":111914,"kind":"organization","name":"Sumitomo Chemical Co., Ltd.","position":1,"cik":"0001798550","reported_name":"Sumitomo Chemical Co., Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111915,"kind":"organization","name":"Sumitomo Pharma Co., Ltd.","position":2,"cik":"0001446601","reported_name":"Dainippon Sumitomo Pharma Co Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":115694,"kind":"organization","name":"Sumitovant Biopharma Ltd.","position":3,"cik":"0001798244","reported_name":"Sumitovant Biopharma Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-05-07T13:26:52.000Z","date":"2020-05-05","kind":"purchase","acquired":true,"shares":50000,"price":12.2415,"value":612075.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"This acquisition of a total of 50,000 ordinary shares on the open market is pursuant to the 10b5-1 Trading Plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in column 4 is the average stock price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Sumitovant directly owns 48,247,693 shares of Common Stock. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon, which is a 51.76% owned subsidiary of Sumitomo Chemical. Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein."}],"balance_after":48247693,"source":{"system":"sec-edgar","filing":"0000899243-20-012209","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1798550/000089924320012209/doc4.xml","form_type":"4"}},{"id":3158215,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":111914,"kind":"organization","name":"Sumitomo Chemical Co., Ltd.","position":1,"cik":"0001798550","reported_name":"Sumitomo Chemical Co., Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111915,"kind":"organization","name":"Sumitomo Pharma Co., Ltd.","position":2,"cik":"0001446601","reported_name":"Dainippon Sumitomo Pharma Co Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":115694,"kind":"organization","name":"Sumitovant Biopharma Ltd.","position":3,"cik":"0001798244","reported_name":"Sumitovant Biopharma Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-05-07T13:26:52.000Z","date":"2020-05-05","kind":"purchase","acquired":true,"shares":50000,"price":11.6893,"value":584465.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This acquisition of a total of 50,000 ordinary shares on the open market is pursuant to a Rule 10b5-1 Stock Trading Plan entered into by the Reporting Person on March 13, 2020 (the \"10b5-1 Trading Plan\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in column 4 is the average stock price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Sumitovant Biopharma Ltd. (\"Sumitovant\") directly owns 48,197,693 shares of Common Stock. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd. (\"Sumitomo Dainippon\"), which is a 51.76% owned subsidiary of Sumitomo Chemical Co., Ltd. (\"Sumitomo Chemical\"). Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein."}],"balance_after":48197693,"source":{"system":"sec-edgar","filing":"0000899243-20-012209","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1798550/000089924320012209/doc4.xml","form_type":"4"}},{"id":3161472,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":111914,"kind":"organization","name":"Sumitomo Chemical Co., Ltd.","position":1,"cik":"0001798550","reported_name":"Sumitomo Chemical Co., Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111915,"kind":"organization","name":"Sumitomo Pharma Co., Ltd.","position":2,"cik":"0001446601","reported_name":"Dainippon Sumitomo Pharma Co Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":115694,"kind":"organization","name":"Sumitovant Biopharma Ltd.","position":3,"cik":"0001798244","reported_name":"Sumitovant Biopharma Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-05-05T19:40:43.000Z","date":"2020-05-04","kind":"purchase","acquired":true,"shares":50000,"price":11.4974,"value":574870.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"This acquisition of a total of 50,000 ordinary shares on the open market is pursuant to the 10b5-1 Trading Plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in column 4 is the average stock price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Sumitovant directly owns 48,147,693 shares of Common Stock. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon, which is a 51.76% owned subsidiary of Sumitomo Chemical. Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein."}],"balance_after":48147693,"source":{"system":"sec-edgar","filing":"0000899243-20-012040","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1798550/000089924320012040/doc4.xml","form_type":"4"}},{"id":3161471,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":111914,"kind":"organization","name":"Sumitomo Chemical Co., Ltd.","position":1,"cik":"0001798550","reported_name":"Sumitomo Chemical Co., Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111915,"kind":"organization","name":"Sumitomo Pharma Co., Ltd.","position":2,"cik":"0001446601","reported_name":"Dainippon Sumitomo Pharma Co Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":115694,"kind":"organization","name":"Sumitovant Biopharma Ltd.","position":3,"cik":"0001798244","reported_name":"Sumitovant Biopharma Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-05-05T19:40:43.000Z","date":"2020-05-01","kind":"purchase","acquired":true,"shares":50000,"price":11.3836,"value":569180.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This acquisition of a total of 50,000 ordinary shares on the open market is pursuant to a Rule 10b5-1 Stock Trading Plan entered into by the Reporting Person on March 13, 2020 (the \"10b5-1 Trading Plan\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in column 4 is the average stock price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Sumitovant Biopharma Ltd. (\"Sumitovant\") directly owns 48,097,693 shares of Common Stock. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd. (\"Sumitomo Dainippon\"), which is a 51.76% owned subsidiary of Sumitomo Chemical Co., Ltd. (\"Sumitomo Chemical\"). Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein."}],"balance_after":48097693,"source":{"system":"sec-edgar","filing":"0000899243-20-012040","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1798550/000089924320012040/doc4.xml","form_type":"4"}},{"id":3165539,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":111914,"kind":"organization","name":"Sumitomo Chemical Co., Ltd.","position":1,"cik":"0001798550","reported_name":"Sumitomo Chemical Co., Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111915,"kind":"organization","name":"Sumitomo Pharma Co., Ltd.","position":2,"cik":"0001446601","reported_name":"Dainippon Sumitomo Pharma Co Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":115694,"kind":"organization","name":"Sumitovant Biopharma Ltd.","position":3,"cik":"0001798244","reported_name":"Sumitovant Biopharma Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-05-01T21:35:34.000Z","date":"2020-04-30","kind":"purchase","acquired":true,"shares":50000,"price":12.0765,"value":603825.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"This acquisition of a total of 50,000 ordinary shares on the open market is pursuant to the 10b5-1 Trading Plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in column 4 is the average stock price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Sumitovant directly owns 48,047,693 shares of Common Stock. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon, which is a 51.76% owned subsidiary of Sumitomo Chemical. Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein."}],"balance_after":48047693,"source":{"system":"sec-edgar","filing":"0000899243-20-011728","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1798550/000089924320011728/doc4.xml","form_type":"4"}},{"id":3165538,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":111914,"kind":"organization","name":"Sumitomo Chemical Co., Ltd.","position":1,"cik":"0001798550","reported_name":"Sumitomo Chemical Co., Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111915,"kind":"organization","name":"Sumitomo Pharma Co., Ltd.","position":2,"cik":"0001446601","reported_name":"Dainippon Sumitomo Pharma Co Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":115694,"kind":"organization","name":"Sumitovant Biopharma Ltd.","position":3,"cik":"0001798244","reported_name":"Sumitovant Biopharma Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-05-01T21:35:34.000Z","date":"2020-04-29","kind":"purchase","acquired":true,"shares":50000,"price":11.9179,"value":595895.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This acquisition of a total of 50,000 ordinary shares on the open market is pursuant to a Rule 10b5-1 Stock Trading Plan entered into by the Reporting Person on March 13, 2020 (the \"10b5-1 Trading Plan\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in column 4 is the average stock price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Sumitovant Biopharma Ltd. (\"Sumitovant\") directly owns 47,997,693 shares of Common Stock. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd. (\"Sumitomo Dainippon\"), which is a 51.76% owned subsidiary of Sumitomo Chemical Co., Ltd. (\"Sumitomo Chemical\"). Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein."}],"balance_after":47997693,"source":{"system":"sec-edgar","filing":"0000899243-20-011728","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1798550/000089924320011728/doc4.xml","form_type":"4"}},{"id":3167511,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":111914,"kind":"organization","name":"Sumitomo Chemical Co., Ltd.","position":1,"cik":"0001798550","reported_name":"Sumitomo Chemical Co., Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111915,"kind":"organization","name":"Sumitomo Pharma Co., Ltd.","position":2,"cik":"0001446601","reported_name":"Dainippon Sumitomo Pharma Co Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":115694,"kind":"organization","name":"Sumitovant Biopharma Ltd.","position":3,"cik":"0001798244","reported_name":"Sumitovant Biopharma Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-04-29T17:38:34.000Z","date":"2020-04-28","kind":"purchase","acquired":true,"shares":50000,"price":12.0544,"value":602720.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"This acquisition of a total of 50,000 ordinary shares on the open market is pursuant to the 10b5-1 Trading Plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in column 4 is the average stock price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Sumitovant directly owns 47,947,693 shares of Common Stock. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon, which is a 51.76% owned subsidiary of Sumitomo Chemical. Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein."}],"balance_after":47947693,"source":{"system":"sec-edgar","filing":"0000899243-20-011506","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1798550/000089924320011506/doc4.xml","form_type":"4"}},{"id":3167510,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":111914,"kind":"organization","name":"Sumitomo Chemical Co., Ltd.","position":1,"cik":"0001798550","reported_name":"Sumitomo Chemical Co., Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111915,"kind":"organization","name":"Sumitomo Pharma Co., Ltd.","position":2,"cik":"0001446601","reported_name":"Dainippon Sumitomo Pharma Co Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":115694,"kind":"organization","name":"Sumitovant Biopharma Ltd.","position":3,"cik":"0001798244","reported_name":"Sumitovant Biopharma Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-04-29T17:38:34.000Z","date":"2020-04-27","kind":"purchase","acquired":true,"shares":40503,"price":12.1794,"value":493302.2382,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This acquisition of a total of 40,503 ordinary shares on the open market is pursuant to a Rule 10b5-1 Stock Trading Plan entered into by the Reporting Person on March 13, 2020 (the \"10b5-1 Trading Plan\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in column 4 is the average stock price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Sumitovant Biopharma Ltd. (\"Sumitovant\") directly owns 47,897,693 shares of Common Stock. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd. (\"Sumitomo Dainippon\"), which is a 51.76% owned subsidiary of Sumitomo Chemical Co., Ltd. (\"Sumitomo Chemical\"). Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein."}],"balance_after":47897693,"source":{"system":"sec-edgar","filing":"0000899243-20-011506","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1798550/000089924320011506/doc4.xml","form_type":"4"}},{"id":3169156,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":111914,"kind":"organization","name":"Sumitomo Chemical Co., Ltd.","position":1,"cik":"0001798550","reported_name":"Sumitomo Chemical Co., Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111915,"kind":"organization","name":"Sumitomo Pharma Co., Ltd.","position":2,"cik":"0001446601","reported_name":"Dainippon Sumitomo Pharma Co Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":115694,"kind":"organization","name":"Sumitovant Biopharma Ltd.","position":3,"cik":"0001798244","reported_name":"Sumitovant Biopharma Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-04-27T15:30:37.000Z","date":"2020-04-24","kind":"purchase","acquired":true,"shares":43086,"price":12.1465,"value":523344.099,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"This acquisition of a total of 43,086 ordinary shares on the open market is pursuant to the 10b5-1 Trading Plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in column 4 is the average stock price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Sumitovant directly owns 47,857,190 shares of Common Stock. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon, which is a 51.76% owned subsidiary of Sumitomo Chemical. Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein."}],"balance_after":47857190,"source":{"system":"sec-edgar","filing":"0000899243-20-011334","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1798550/000089924320011334/doc4.xml","form_type":"4"}},{"id":3169155,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":111914,"kind":"organization","name":"Sumitomo Chemical Co., Ltd.","position":1,"cik":"0001798550","reported_name":"Sumitomo Chemical Co., Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111915,"kind":"organization","name":"Sumitomo Pharma Co., Ltd.","position":2,"cik":"0001446601","reported_name":"Dainippon Sumitomo Pharma Co Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":115694,"kind":"organization","name":"Sumitovant Biopharma Ltd.","position":3,"cik":"0001798244","reported_name":"Sumitovant Biopharma Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-04-27T15:30:37.000Z","date":"2020-04-23","kind":"purchase","acquired":true,"shares":35000,"price":12.3458,"value":432103.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This acquisition of a total of 35,000 ordinary shares on the open market is pursuant to a Rule 10b5-1 Stock Trading Plan entered into by the Reporting Person on March 13, 2020 (the \"10b5-1 Trading Plan\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in column 4 is the average stock price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Sumitovant Biopharma Ltd. (\"Sumitovant\") directly owns 47,814,104 shares of Common Stock. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd. (\"Sumitomo Dainippon\"), which is a 51.76% owned subsidiary of Sumitomo Chemical Co., Ltd. (\"Sumitomo Chemical\"). Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein."}],"balance_after":47814104,"source":{"system":"sec-edgar","filing":"0000899243-20-011334","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1798550/000089924320011334/doc4.xml","form_type":"4"}},{"id":3171159,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":111914,"kind":"organization","name":"Sumitomo Chemical Co., Ltd.","position":1,"cik":"0001798550","reported_name":"Sumitomo Chemical Co., Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111915,"kind":"organization","name":"Sumitomo Pharma Co., Ltd.","position":2,"cik":"0001446601","reported_name":"Dainippon Sumitomo Pharma Co Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":115694,"kind":"organization","name":"Sumitovant Biopharma Ltd.","position":3,"cik":"0001798244","reported_name":"Sumitovant Biopharma Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-04-23T18:21:26.000Z","date":"2020-04-22","kind":"purchase","acquired":true,"shares":50000,"price":11.9346,"value":596730.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"This acquisition of a total of 50,000 ordinary shares on the open market is pursuant to the 10b5-1 Trading Plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in column 4 is the average stock price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Sumitovant directly owns 47,779,104 shares of Common Stock. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon, which is a 51.76% owned subsidiary of Sumitomo Chemical. Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein."}],"balance_after":47779104,"source":{"system":"sec-edgar","filing":"0000899243-20-011209","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1798550/000089924320011209/doc4.xml","form_type":"4"}},{"id":3171158,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":111914,"kind":"organization","name":"Sumitomo Chemical Co., Ltd.","position":1,"cik":"0001798550","reported_name":"Sumitomo Chemical Co., Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111915,"kind":"organization","name":"Sumitomo Pharma Co., Ltd.","position":2,"cik":"0001446601","reported_name":"Dainippon Sumitomo Pharma Co Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":115694,"kind":"organization","name":"Sumitovant Biopharma Ltd.","position":3,"cik":"0001798244","reported_name":"Sumitovant Biopharma Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-04-23T18:21:26.000Z","date":"2020-04-21","kind":"purchase","acquired":true,"shares":50200,"price":11.5765,"value":581140.3,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This acquisition of a total of 50,200 ordinary shares on the open market is pursuant to a Rule 10b5-1 Stock Trading Plan entered into by the Reporting Person on March 13, 2020 (the \"10b5-1 Trading Plan\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in column 4 is the average stock price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Sumitovant Biopharma Ltd. (\"Sumitovant\") directly owns 47,729,104 shares of Common Stock. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd. (\"Sumitomo Dainippon\"), which is a 51.76% owned subsidiary of Sumitomo Chemical Co., Ltd. (\"Sumitomo Chemical\"). Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein."}],"balance_after":47729104,"source":{"system":"sec-edgar","filing":"0000899243-20-011209","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1798550/000089924320011209/doc4.xml","form_type":"4"}},{"id":3172492,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":111914,"kind":"organization","name":"Sumitomo Chemical Co., Ltd.","position":1,"cik":"0001798550","reported_name":"Sumitomo Chemical Co., Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111915,"kind":"organization","name":"Sumitomo Pharma Co., Ltd.","position":2,"cik":"0001446601","reported_name":"Dainippon Sumitomo Pharma Co Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":115694,"kind":"organization","name":"Sumitovant Biopharma Ltd.","position":3,"cik":"0001798244","reported_name":"Sumitovant Biopharma Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-04-21T20:01:04.000Z","date":"2020-04-20","kind":"purchase","acquired":true,"shares":50300,"price":11.8176,"value":594425.28,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"This acquisition of a total of 50,300 ordinary shares on the open market is pursuant to the 10b5-1 Trading Plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in column 4 is the average stock price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Sumitovant directly owns 47,678,904 shares of Common Stock. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon, which is a 51.76% owned subsidiary of Sumitomo Chemical. Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein."}],"balance_after":47678904,"source":{"system":"sec-edgar","filing":"0000899243-20-011041","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1798550/000089924320011041/doc4.xml","form_type":"4"}},{"id":3172491,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":111914,"kind":"organization","name":"Sumitomo Chemical Co., Ltd.","position":1,"cik":"0001798550","reported_name":"Sumitomo Chemical Co., Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111915,"kind":"organization","name":"Sumitomo Pharma Co., Ltd.","position":2,"cik":"0001446601","reported_name":"Dainippon Sumitomo Pharma Co Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":115694,"kind":"organization","name":"Sumitovant Biopharma Ltd.","position":3,"cik":"0001798244","reported_name":"Sumitovant Biopharma Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-04-21T20:01:04.000Z","date":"2020-04-17","kind":"purchase","acquired":true,"shares":70000,"price":10.7648,"value":753536.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This acquisition of a total of 70,000 ordinary shares on the open market is pursuant to a Rule 10b5-1 Stock Trading Plan entered into by the Reporting Person on March 13, 2020 (the \"10b5-1 Trading Plan\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in column 4 is the average stock price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Sumitovant Biopharma Ltd. (\"Sumitovant\") directly owns 47,628,604 shares of Common Stock. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd. (\"Sumitomo Dainippon\"), which is a 51.76% owned subsidiary of Sumitomo Chemical Co., Ltd. (\"Sumitomo Chemical\"). Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein."}],"balance_after":47628604,"source":{"system":"sec-edgar","filing":"0000899243-20-011041","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1798550/000089924320011041/doc4.xml","form_type":"4"}},{"id":3174288,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":111914,"kind":"organization","name":"Sumitomo Chemical Co., Ltd.","position":1,"cik":"0001798550","reported_name":"Sumitomo Chemical Co., Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111915,"kind":"organization","name":"Sumitomo Pharma Co., Ltd.","position":2,"cik":"0001446601","reported_name":"Dainippon Sumitomo Pharma Co Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":115694,"kind":"organization","name":"Sumitovant Biopharma Ltd.","position":3,"cik":"0001798244","reported_name":"Sumitovant Biopharma Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-04-17T16:38:12.000Z","date":"2020-04-16","kind":"purchase","acquired":true,"shares":70000,"price":10.6382,"value":744674.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"This acquisition of a total of 70,000 ordinary shares on the open market is pursuant to the 10b5-1 Trading Plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in column 4 is the average stock price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Sumitovant directly owns 47,558,604 shares of Common Stock. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon, which is a 51.76% owned subsidiary of Sumitomo Chemical. Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein."}],"balance_after":47558604,"source":{"system":"sec-edgar","filing":"0000899243-20-010899","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1798550/000089924320010899/doc4.xml","form_type":"4"}},{"id":3174287,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":111914,"kind":"organization","name":"Sumitomo Chemical Co., Ltd.","position":1,"cik":"0001798550","reported_name":"Sumitomo Chemical Co., Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111915,"kind":"organization","name":"Sumitomo Pharma Co., Ltd.","position":2,"cik":"0001446601","reported_name":"Dainippon Sumitomo Pharma Co Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":115694,"kind":"organization","name":"Sumitovant Biopharma Ltd.","position":3,"cik":"0001798244","reported_name":"Sumitovant Biopharma Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-04-17T16:38:12.000Z","date":"2020-04-15","kind":"purchase","acquired":true,"shares":70000,"price":10.4814,"value":733698.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This acquisition of a total of 70,000 ordinary shares on the open market is pursuant to a Rule 10b5-1 Stock Trading Plan entered into by the Reporting Person on March 13, 2020 (the \"10b5-1 Trading Plan\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in column 4 is the average stock price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Sumitovant Biopharma Ltd. (\"Sumitovant\") directly owns 47,488,604 shares of Common Stock. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd. (\"Sumitomo Dainippon\"), which is a 51.76% owned subsidiary of Sumitomo Chemical Co., Ltd. (\"Sumitomo Chemical\"). Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein."}],"balance_after":47488604,"source":{"system":"sec-edgar","filing":"0000899243-20-010899","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1798550/000089924320010899/doc4.xml","form_type":"4"}},{"id":3176586,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":111914,"kind":"organization","name":"Sumitomo Chemical Co., Ltd.","position":1,"cik":"0001798550","reported_name":"Sumitomo Chemical Co., Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111915,"kind":"organization","name":"Sumitomo Pharma Co., Ltd.","position":2,"cik":"0001446601","reported_name":"Dainippon Sumitomo Pharma Co Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":115694,"kind":"organization","name":"Sumitovant Biopharma Ltd.","position":3,"cik":"0001798244","reported_name":"Sumitovant Biopharma Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-04-15T23:22:36.000Z","date":"2020-04-14","kind":"purchase","acquired":true,"shares":70000,"price":11.0015,"value":770105.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"This acquisition of a total of 70,000 ordinary shares on the open market is pursuant to the 10b5-1 Trading Plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in column 4 is the average stock price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Sumitovant directly owns 47,418,604 shares of Common Stock. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon, which is a 51.76% owned subsidiary of Sumitomo Chemical. Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein."}],"balance_after":47418604,"source":{"system":"sec-edgar","filing":"0000899243-20-010804","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1798550/000089924320010804/doc4.xml","form_type":"4"}},{"id":3176585,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":111914,"kind":"organization","name":"Sumitomo Chemical Co., Ltd.","position":1,"cik":"0001798550","reported_name":"Sumitomo Chemical Co., Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111915,"kind":"organization","name":"Sumitomo Pharma Co., Ltd.","position":2,"cik":"0001446601","reported_name":"Dainippon Sumitomo Pharma Co Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":115694,"kind":"organization","name":"Sumitovant Biopharma Ltd.","position":3,"cik":"0001798244","reported_name":"Sumitovant Biopharma Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-04-15T23:22:36.000Z","date":"2020-04-13","kind":"purchase","acquired":true,"shares":70000,"price":9.8078,"value":686546.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This acquisition of a total of 70,000 ordinary shares on the open market is pursuant to a Rule 10b5-1 Stock Trading Plan entered into by the Reporting Person on March 13, 2020 (the \"10b5-1 Trading Plan\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in column 4 is the average stock price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Sumitovant Biopharma Ltd. (\"Sumitovant\") directly owns 47,348,604 shares of Common Stock. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd. (\"Sumitomo Dainippon\"), which is a 51.76% owned subsidiary of Sumitomo Chemical Co., Ltd. (\"Sumitomo Chemical\"). Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein."}],"balance_after":47348604,"source":{"system":"sec-edgar","filing":"0000899243-20-010804","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1798550/000089924320010804/doc4.xml","form_type":"4"}},{"id":3178047,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":111914,"kind":"organization","name":"Sumitomo Chemical Co., Ltd.","position":1,"cik":"0001798550","reported_name":"Sumitomo Chemical Co., Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111915,"kind":"organization","name":"Sumitomo Pharma Co., Ltd.","position":2,"cik":"0001446601","reported_name":"Dainippon Sumitomo Pharma Co Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":115694,"kind":"organization","name":"Sumitovant Biopharma Ltd.","position":3,"cik":"0001798244","reported_name":"Sumitovant Biopharma Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-04-13T18:25:33.000Z","date":"2020-04-09","kind":"purchase","acquired":true,"shares":70000,"price":9.3667,"value":655669.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This acquisition of a total of 70,000 ordinary shares on the open market is pursuant to a Rule 10b5-1 Stock Trading Plan entered into by the Reporting Person on March 13, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in column 4 is the average stock price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Sumitovant Biopharma Ltd. (\"Sumitovant\") directly owns 47,278,604 shares of Common Stock. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd. (\"Sumitomo Dainippon\"), which is a 51.76% owned subsidiary of Sumitomo Chemical Co., Ltd. (\"Sumitomo Chemical\"). Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein."}],"balance_after":47278604,"source":{"system":"sec-edgar","filing":"0000899243-20-010666","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1798550/000089924320010666/doc4.xml","form_type":"4"}},{"id":3179090,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":111914,"kind":"organization","name":"Sumitomo Chemical Co., Ltd.","position":1,"cik":"0001798550","reported_name":"Sumitomo Chemical Co., Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111915,"kind":"organization","name":"Sumitomo Pharma Co., Ltd.","position":2,"cik":"0001446601","reported_name":"Dainippon Sumitomo Pharma Co Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":115694,"kind":"organization","name":"Sumitovant Biopharma Ltd.","position":3,"cik":"0001798244","reported_name":"Sumitovant Biopharma Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-04-09T15:20:36.000Z","date":"2020-04-08","kind":"purchase","acquired":true,"shares":70000,"price":8.5277,"value":596939.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"This acquisition of a total of 70,000 ordinary shares on the open market is pursuant to the 10b5-1 Trading Plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in column 4 is the average stock price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Sumitovant directly owns 47,208,604 shares of Common Stock. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon, which is a 51.76% owned subsidiary of Sumitomo Chemical. Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein."}],"balance_after":47208604,"source":{"system":"sec-edgar","filing":"0000899243-20-010563","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1798550/000089924320010563/doc4.xml","form_type":"4"}},{"id":3179089,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":111914,"kind":"organization","name":"Sumitomo Chemical Co., Ltd.","position":1,"cik":"0001798550","reported_name":"Sumitomo Chemical Co., Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111915,"kind":"organization","name":"Sumitomo Pharma Co., Ltd.","position":2,"cik":"0001446601","reported_name":"Dainippon Sumitomo Pharma Co Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":115694,"kind":"organization","name":"Sumitovant Biopharma Ltd.","position":3,"cik":"0001798244","reported_name":"Sumitovant Biopharma Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-04-09T15:20:36.000Z","date":"2020-04-07","kind":"purchase","acquired":true,"shares":70000,"price":8.2052,"value":574364.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This acquisition of a total of 70,000 ordinary shares on the open market is pursuant to a Rule 10b5-1 Stock Trading Plan entered into by the Reporting Person on March 13, 2020 (the \"10b5-1 Trading Plan\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in column 4 is the average stock price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Sumitovant Biopharma Ltd. (\"Sumitovant\") directly owns 47,138,604 shares of Common Stock. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd. (\"Sumitomo Dainippon\"), which is a 51.76% owned subsidiary of Sumitomo Chemical Co., Ltd. (\"Sumitomo Chemical\"). Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein."}],"balance_after":47138604,"source":{"system":"sec-edgar","filing":"0000899243-20-010563","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1798550/000089924320010563/doc4.xml","form_type":"4"}},{"id":3180790,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":111914,"kind":"organization","name":"Sumitomo Chemical Co., Ltd.","position":1,"cik":"0001798550","reported_name":"Sumitomo Chemical Co., Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111915,"kind":"organization","name":"Sumitomo Pharma Co., Ltd.","position":2,"cik":"0001446601","reported_name":"Dainippon Sumitomo Pharma Co Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":115694,"kind":"organization","name":"Sumitovant Biopharma Ltd.","position":3,"cik":"0001798244","reported_name":"Sumitovant Biopharma Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-04-07T17:56:32.000Z","date":"2020-04-06","kind":"purchase","acquired":true,"shares":70000,"price":8.436,"value":590520.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"This acquisition of a total of 70,000 ordinary shares on the open market is pursuant to the 10b5-1 Trading Plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in column 4 is the average stock price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Sumitovant directly owns 47,068,604 shares of Common Stock. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon, which is a 51.76% owned subsidiary of Sumitomo Chemical. Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein."}],"balance_after":47068604,"source":{"system":"sec-edgar","filing":"0000899243-20-010382","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1798550/000089924320010382/doc4.xml","form_type":"4"}},{"id":3180789,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":111914,"kind":"organization","name":"Sumitomo Chemical Co., Ltd.","position":1,"cik":"0001798550","reported_name":"Sumitomo Chemical Co., Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111915,"kind":"organization","name":"Sumitomo Pharma Co., Ltd.","position":2,"cik":"0001446601","reported_name":"Dainippon Sumitomo Pharma Co Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":115694,"kind":"organization","name":"Sumitovant Biopharma Ltd.","position":3,"cik":"0001798244","reported_name":"Sumitovant Biopharma Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-04-07T17:56:32.000Z","date":"2020-04-03","kind":"purchase","acquired":true,"shares":70000,"price":7.9275,"value":554925.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This acquisition of a total of 70,000 ordinary shares on the open market is pursuant to a Rule 10b5-1 Stock Trading Plan entered into by the Reporting Person on March 13, 2020 (the \"10b5-1 Trading Plan\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in column 4 is the average stock price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Sumitovant Biopharma Ltd. (\"Sumitovant\") directly owns 46,998,604 shares of Common Stock. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd. (\"Sumitomo Dainippon\"), which is a 51.76% owned subsidiary of Sumitomo Chemical Co., Ltd. (\"Sumitomo Chemical\"). Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein."}],"balance_after":46998604,"source":{"system":"sec-edgar","filing":"0000899243-20-010382","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1798550/000089924320010382/doc4.xml","form_type":"4"}},{"id":3183814,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":111914,"kind":"organization","name":"Sumitomo Chemical Co., Ltd.","position":1,"cik":"0001798550","reported_name":"Sumitomo Chemical Co., Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111915,"kind":"organization","name":"Sumitomo Pharma Co., Ltd.","position":2,"cik":"0001446601","reported_name":"Dainippon Sumitomo Pharma Co Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":115694,"kind":"organization","name":"Sumitovant Biopharma Ltd.","position":3,"cik":"0001798244","reported_name":"Sumitovant Biopharma Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-04-03T19:04:00.000Z","date":"2020-04-02","kind":"purchase","acquired":true,"shares":70000,"price":7.7298,"value":541086.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"This acquisition of a total of 70,000 ordinary shares on the open market is pursuant to the 10b5-1 Trading Plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in column 4 is the average stock price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Sumitovant directly owns 46,928,604 shares of Common Stock. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon, which is a 51.76% owned subsidiary of Sumitomo Chemical. Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein."}],"balance_after":46928604,"source":{"system":"sec-edgar","filing":"0000899243-20-010095","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1798550/000089924320010095/doc4.xml","form_type":"4"}},{"id":3183813,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":111914,"kind":"organization","name":"Sumitomo Chemical Co., Ltd.","position":1,"cik":"0001798550","reported_name":"Sumitomo Chemical Co., Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111915,"kind":"organization","name":"Sumitomo Pharma Co., Ltd.","position":2,"cik":"0001446601","reported_name":"Dainippon Sumitomo Pharma Co Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":115694,"kind":"organization","name":"Sumitovant Biopharma Ltd.","position":3,"cik":"0001798244","reported_name":"Sumitovant Biopharma Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-04-03T19:04:00.000Z","date":"2020-04-01","kind":"purchase","acquired":true,"shares":70000,"price":7.4614,"value":522298.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This acquisition of a total of 70,000 ordinary shares on the open market is pursuant to a Rule 10b5-1 Stock Trading Plan entered into by the Reporting Person on March 13, 2020 (the \"10b5-1 Trading Plan\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in column 4 is the average stock price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Sumitovant Biopharma Ltd. (\"Sumitovant\") directly owns 46,858,604 shares of Common Stock. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd. (\"Sumitomo Dainippon\"), which is a 51.76% owned subsidiary of Sumitomo Chemical Co., Ltd. (\"Sumitomo Chemical\"). Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein."}],"balance_after":46858604,"source":{"system":"sec-edgar","filing":"0000899243-20-010095","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1798550/000089924320010095/doc4.xml","form_type":"4"}},{"id":3189442,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":111914,"kind":"organization","name":"Sumitomo Chemical Co., Ltd.","position":1,"cik":"0001798550","reported_name":"Sumitomo Chemical Co., Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111915,"kind":"organization","name":"Sumitomo Pharma Co., Ltd.","position":2,"cik":"0001446601","reported_name":"Dainippon Sumitomo Pharma Co Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":115694,"kind":"organization","name":"Sumitovant Biopharma Ltd.","position":3,"cik":"0001798244","reported_name":"Sumitovant Biopharma Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-04-01T14:55:55.000Z","date":"2020-03-31","kind":"purchase","acquired":true,"shares":70000,"price":7.9712,"value":557984.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"This acquisition of a total of 70,000 ordinary shares on the open market is pursuant to the 10b5-1 Trading Plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in column 4 is the average stock price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Sumitovant directly owns 46,788,604 shares of Common Stock. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon, which is a 51.76% owned subsidiary of Sumitomo Chemical. Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein."}],"balance_after":46788604,"source":{"system":"sec-edgar","filing":"0000899243-20-009776","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1798550/000089924320009776/doc4.xml","form_type":"4"}},{"id":3189441,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":111914,"kind":"organization","name":"Sumitomo Chemical Co., Ltd.","position":1,"cik":"0001798550","reported_name":"Sumitomo Chemical Co., Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111915,"kind":"organization","name":"Sumitomo Pharma Co., Ltd.","position":2,"cik":"0001446601","reported_name":"Dainippon Sumitomo Pharma Co Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":115694,"kind":"organization","name":"Sumitovant Biopharma Ltd.","position":3,"cik":"0001798244","reported_name":"Sumitovant Biopharma Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-04-01T14:55:55.000Z","date":"2020-03-30","kind":"purchase","acquired":true,"shares":70000,"price":7.6538,"value":535766.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This acquisition of a total of 70,000 ordinary shares on the open market is pursuant to a Rule 10b5-1 Stock Trading Plan entered into by the Reporting Person on March 13, 2020 (the \"10b5-1 Trading Plan\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in column 4 is the average stock price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Sumitovant Biopharma Ltd. (\"Sumitovant\") directly owns 46,718,604 shares of Common Stock. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd. (\"Sumitomo Dainippon\"), which is a 51.76% owned subsidiary of Sumitomo Chemical Co., Ltd. (\"Sumitomo Chemical\"). Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein."}],"balance_after":46718604,"source":{"system":"sec-edgar","filing":"0000899243-20-009776","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1798550/000089924320009776/doc4.xml","form_type":"4"}},{"id":3192226,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":111914,"kind":"organization","name":"Sumitomo Chemical Co., Ltd.","position":1,"cik":"0001798550","reported_name":"Sumitomo Chemical Co., Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111915,"kind":"organization","name":"Sumitomo Pharma Co., Ltd.","position":2,"cik":"0001446601","reported_name":"Dainippon Sumitomo Pharma Co Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":115694,"kind":"organization","name":"Sumitovant Biopharma Ltd.","position":3,"cik":"0001798244","reported_name":"Sumitovant Biopharma Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-03-30T15:34:19.000Z","date":"2020-03-27","kind":"purchase","acquired":true,"shares":70000,"price":7.975,"value":558250.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"This acquisition of a total of 70,000 ordinary shares on the open market is pursuant to the 10b5-1 Trading Plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in column 4 is the average stock price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Sumitovant directly owns 46,648,604 shares of Common Stock. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon, which is a 51.76% owned subsidiary of Sumitomo Chemical. Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein."}],"balance_after":46648604,"source":{"system":"sec-edgar","filing":"0000899243-20-009633","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1798550/000089924320009633/doc4.xml","form_type":"4"}},{"id":3192225,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":111914,"kind":"organization","name":"Sumitomo Chemical Co., Ltd.","position":1,"cik":"0001798550","reported_name":"Sumitomo Chemical Co., Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111915,"kind":"organization","name":"Sumitomo Pharma Co., Ltd.","position":2,"cik":"0001446601","reported_name":"Dainippon Sumitomo Pharma Co Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":115694,"kind":"organization","name":"Sumitovant Biopharma Ltd.","position":3,"cik":"0001798244","reported_name":"Sumitovant Biopharma Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-03-30T15:34:19.000Z","date":"2020-03-26","kind":"purchase","acquired":true,"shares":70000,"price":7.9401,"value":555807.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This acquisition of a total of 70,000 ordinary shares on the open market is pursuant to a Rule 10b5-1 Stock Trading Plan entered into by the Reporting Person on March 13, 2020 (the \"10b5-1 Trading Plan\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in column 4 is the average stock price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Sumitovant Biopharma Ltd. (\"Sumitovant\") directly owns 46,578,604 shares of Common Stock. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd. (\"Sumitomo Dainippon\"), which is a 51.76% owned subsidiary of Sumitomo Chemical Co., Ltd. (\"Sumitomo Chemical\"). Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein."}],"balance_after":46578604,"source":{"system":"sec-edgar","filing":"0000899243-20-009633","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1798550/000089924320009633/doc4.xml","form_type":"4"}},{"id":3194489,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":111914,"kind":"organization","name":"Sumitomo Chemical Co., Ltd.","position":1,"cik":"0001798550","reported_name":"Sumitomo Chemical Co., Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111915,"kind":"organization","name":"Sumitomo Pharma Co., Ltd.","position":2,"cik":"0001446601","reported_name":"Dainippon Sumitomo Pharma Co Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":115694,"kind":"organization","name":"Sumitovant Biopharma Ltd.","position":3,"cik":"0001798244","reported_name":"Sumitovant Biopharma Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-03-26T15:39:34.000Z","date":"2020-03-25","kind":"purchase","acquired":true,"shares":108100,"price":7.6031,"value":821895.11,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"This acquisition of a total of 108,100 ordinary shares on the open market is pursuant to the 10b5-1 Trading Plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in column 4 is the average stock price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Sumitovant directly owns 46,508,604 shares of Common Stock. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon, which is a 51.76% owned subsidiary of Sumitomo Chemical. Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein."}],"balance_after":46508604,"source":{"system":"sec-edgar","filing":"0000899243-20-009469","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1798550/000089924320009469/doc4.xml","form_type":"4"}},{"id":3194488,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":111914,"kind":"organization","name":"Sumitomo Chemical Co., Ltd.","position":1,"cik":"0001798550","reported_name":"Sumitomo Chemical Co., Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111915,"kind":"organization","name":"Sumitomo Pharma Co., Ltd.","position":2,"cik":"0001446601","reported_name":"Dainippon Sumitomo Pharma Co Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":115694,"kind":"organization","name":"Sumitovant Biopharma Ltd.","position":3,"cik":"0001798244","reported_name":"Sumitovant Biopharma Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-03-26T15:39:34.000Z","date":"2020-03-24","kind":"purchase","acquired":true,"shares":211200,"price":7.6731,"value":1620558.72,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This acquisition of a total of 211,200 ordinary shares on the open market is pursuant to a Rule 10b5-1 Stock Trading Plan entered into by the Reporting Person on March 13, 2020 (the \"10b5-1 Trading Plan\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in column 4 is the average stock price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Sumitovant Biopharma Ltd. (\"Sumitovant\") directly owns 46,400,504 shares of Common Stock. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd. (\"Sumitomo Dainippon\"), which is a 51.76% owned subsidiary of Sumitomo Chemical Co., Ltd. (\"Sumitomo Chemical\"). Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein."}],"balance_after":46400504,"source":{"system":"sec-edgar","filing":"0000899243-20-009469","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1798550/000089924320009469/doc4.xml","form_type":"4"}},{"id":3196620,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":111914,"kind":"organization","name":"Sumitomo Chemical Co., Ltd.","position":1,"cik":"0001798550","reported_name":"Sumitomo Chemical Co., Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111915,"kind":"organization","name":"Sumitomo Pharma Co., Ltd.","position":2,"cik":"0001446601","reported_name":"Dainippon Sumitomo Pharma Co Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":115694,"kind":"organization","name":"Sumitovant Biopharma Ltd.","position":3,"cik":"0001798244","reported_name":"Sumitovant Biopharma Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-03-24T19:15:21.000Z","date":"2020-03-23","kind":"purchase","acquired":true,"shares":211200,"price":7.6796,"value":1621931.52,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"This acquisition of a total of 211,200 ordinary shares on the open market is pursuant to the 10b5-1 Trading Plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in column 4 is the average stock price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Sumitovant directly owns 46,189,304 shares of Common Stock. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon, which is a 51.76% owned subsidiary of Sumitomo Chemical. Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein."}],"balance_after":46189304,"source":{"system":"sec-edgar","filing":"0000899243-20-009332","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1798550/000089924320009332/doc4.xml","form_type":"4"}},{"id":3196619,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":111914,"kind":"organization","name":"Sumitomo Chemical Co., Ltd.","position":1,"cik":"0001798550","reported_name":"Sumitomo Chemical Co., Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111915,"kind":"organization","name":"Sumitomo Pharma Co., Ltd.","position":2,"cik":"0001446601","reported_name":"Dainippon Sumitomo Pharma Co Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":115694,"kind":"organization","name":"Sumitovant Biopharma Ltd.","position":3,"cik":"0001798244","reported_name":"Sumitovant Biopharma Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-03-24T19:15:21.000Z","date":"2020-03-20","kind":"purchase","acquired":true,"shares":193900,"price":7.5952,"value":1472709.28,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This acquisition of a total of 193,900 ordinary shares on the open market is pursuant to a Rule 10b5-1 Stock Trading Plan entered into by the Reporting Person on March 13, 2020 (the \"10b5-1 Trading Plan\")."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in column 4 is the average stock price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Sumitovant Biopharma Ltd. (\"Sumitovant\") directly owns 45,978,104 shares of Common Stock. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd. (\"Sumitomo Dainippon\"), which is a 51.76% owned subsidiary of Sumitomo Chemical Co., Ltd. (\"Sumitomo Chemical\"). Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein."}],"balance_after":45978104,"source":{"system":"sec-edgar","filing":"0000899243-20-009332","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1798550/000089924320009332/doc4.xml","form_type":"4"}},{"id":3199440,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":111914,"kind":"organization","name":"Sumitomo Chemical Co., Ltd.","position":1,"cik":"0001798550","reported_name":"Sumitomo Chemical Co., Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111915,"kind":"organization","name":"Sumitomo Pharma Co., Ltd.","position":2,"cik":"0001446601","reported_name":"Dainippon Sumitomo Pharma Co Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":115694,"kind":"organization","name":"Sumitovant Biopharma Ltd.","position":3,"cik":"0001798244","reported_name":"Sumitovant Biopharma Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-03-20T18:10:58.000Z","date":"2020-03-19","kind":"purchase","acquired":true,"shares":193900,"price":7.679,"value":1488958.1,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This acquisition of a total of 193,900 ordinary shares on the open market is pursuant to a Rule 10b5-1 Stock Trading Plan entered into by the Reporting Person on March 13, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in column 4 is the average stock price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Sumitovant directly owns 45,784,204 shares of Common Stock. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon, which is a 51.76% owned subsidiary of Sumitomo Chemical. Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein."}],"balance_after":45784204,"source":{"system":"sec-edgar","filing":"0000899243-20-009088","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1798550/000089924320009088/doc4.xml","form_type":"4"}},{"id":3199439,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":111914,"kind":"organization","name":"Sumitomo Chemical Co., Ltd.","position":1,"cik":"0001798550","reported_name":"Sumitomo Chemical Co., Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111915,"kind":"organization","name":"Sumitomo Pharma Co., Ltd.","position":2,"cik":"0001446601","reported_name":"Dainippon Sumitomo Pharma Co Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":115694,"kind":"organization","name":"Sumitovant Biopharma Ltd.","position":3,"cik":"0001798244","reported_name":"Sumitovant Biopharma Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-03-20T18:10:58.000Z","date":"2020-03-18","kind":"purchase","acquired":true,"shares":193900,"price":7.4004,"value":1434937.56,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This acquisition of a total of 193,900 ordinary shares on the open market is pursuant to a Rule 10b5-1 Stock Trading Plan entered into by the Reporting Person on March 13, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in column 4 is the average stock price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Sumitovant Biopharma Ltd. (\"Sumitovant\") directly owns 45,590,304 shares of Common Stock. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd. (\"Sumitomo Dainippon\"), which is a 51.76% owned subsidiary of Sumitomo Chemical Co., Ltd. (\"Sumitomo Chemical\"). Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein."}],"balance_after":45590304,"source":{"system":"sec-edgar","filing":"0000899243-20-009088","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1798550/000089924320009088/doc4.xml","form_type":"4"}},{"id":3202907,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":111914,"kind":"organization","name":"Sumitomo Chemical Co., Ltd.","position":1,"cik":"0001798550","reported_name":"Sumitomo Chemical Co., Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111915,"kind":"organization","name":"Sumitomo Pharma Co., Ltd.","position":2,"cik":"0001446601","reported_name":"Dainippon Sumitomo Pharma Co Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":115694,"kind":"organization","name":"Sumitovant Biopharma Ltd.","position":3,"cik":"0001798244","reported_name":"Sumitovant Biopharma Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-03-18T20:21:02.000Z","date":"2020-03-17","kind":"purchase","acquired":true,"shares":193900,"price":7.3953,"value":1433948.67,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This acquisition of a total of 193,900 ordinary shares on the open market is pursuant to a Rule 10b5-1 Stock Trading Plan entered into by the Reporting Person on March 13, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in column 4 is the average stock price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Sumitovant directly owns 45,396,404 shares of Common Stock. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon, which is a 51.76% owned subsidiary of Sumitomo Chemical. Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein."}],"balance_after":45396404,"source":{"system":"sec-edgar","filing":"0000899243-20-008835","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1798550/000089924320008835/doc4.xml","form_type":"4"}},{"id":3202906,"issuer":{"id":115677,"kind":"organization","name":"Myovant Sciences Ltd.","symbol":"MYOV"},"owners":[{"id":111914,"kind":"organization","name":"Sumitomo Chemical Co., Ltd.","position":1,"cik":"0001798550","reported_name":"Sumitomo Chemical Co., Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111915,"kind":"organization","name":"Sumitomo Pharma Co., Ltd.","position":2,"cik":"0001446601","reported_name":"Dainippon Sumitomo Pharma Co Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":115694,"kind":"organization","name":"Sumitovant Biopharma Ltd.","position":3,"cik":"0001798244","reported_name":"Sumitovant Biopharma Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-03-18T20:21:02.000Z","date":"2020-03-16","kind":"purchase","acquired":true,"shares":193900,"price":7.2512,"value":1406007.68,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This acquisition of a total of 193,900 ordinary shares on the open market is pursuant to a Rule 10b5-1 Stock Trading Plan entered into by the Reporting Person on March 13, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in column 4 is the average stock price."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Sumitovant Biopharma Ltd. (\"Sumitovant\") directly owns 45,202,504 shares of Common Stock. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd. (\"Sumitomo Dainippon\"), which is a 51.76% owned subsidiary of Sumitomo Chemical Co., Ltd. (\"Sumitomo Chemical\"). Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein."}],"balance_after":45202504,"source":{"system":"sec-edgar","filing":"0000899243-20-008835","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1798550/000089924320008835/doc4.xml","form_type":"4"}},{"id":3256740,"issuer":{"id":140739,"kind":"organization","name":"Urovant Sciences Ltd.","symbol":"UROV"},"owners":[{"id":111914,"kind":"organization","name":"Sumitomo Chemical Co., Ltd.","position":1,"cik":"0001798550","reported_name":"Sumitomo Chemical Co., Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Footnote (1)"}},{"id":111915,"kind":"organization","name":"Sumitomo Pharma Co., Ltd.","position":2,"cik":"0001446601","reported_name":"Dainippon Sumitomo Pharma Co Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Footnote (1)"}},{"id":115694,"kind":"organization","name":"Sumitovant Biopharma Ltd.","position":3,"cik":"0001798244","reported_name":"Sumitovant Biopharma Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-02-21T22:54:35.000Z","date":"2020-02-19","kind":"purchase","acquired":true,"shares":75212,"price":13.08,"value":983772.96,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Sumitovant Biopharma Ltd. (\"Sumitovant\") directly owns 22,963,263 shares of Common Stock. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd. (\"Sumitomo Dainippon\"), which is a 51.76% owned subsidiary of Sumitomo Chemical Co., Ltd. (\"Sumitomo Chemical\"). Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein."}],"balance_after":22963263,"source":{"system":"sec-edgar","filing":"0000950103-20-003118","document":"dp121731_4-sumitomo.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1798550/000095010320003118/dp121731_4-sumitomo.xml","form_type":"4"}},{"id":3256739,"issuer":{"id":140739,"kind":"organization","name":"Urovant Sciences Ltd.","symbol":"UROV"},"owners":[{"id":111914,"kind":"organization","name":"Sumitomo Chemical Co., Ltd.","position":1,"cik":"0001798550","reported_name":"Sumitomo Chemical Co., Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Footnote (1)"}},{"id":111915,"kind":"organization","name":"Sumitomo Pharma Co., Ltd.","position":2,"cik":"0001446601","reported_name":"Dainippon Sumitomo Pharma Co Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Footnote (1)"}},{"id":115694,"kind":"organization","name":"Sumitovant Biopharma Ltd.","position":3,"cik":"0001798244","reported_name":"Sumitovant Biopharma Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-02-21T22:54:35.000Z","date":"2020-02-19","kind":"purchase","acquired":true,"shares":15165,"price":13.08,"value":198358.2,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Sumitovant Biopharma Ltd. (\"Sumitovant\") directly owns 22,963,263 shares of Common Stock. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd. (\"Sumitomo Dainippon\"), which is a 51.76% owned subsidiary of Sumitomo Chemical Co., Ltd. (\"Sumitomo Chemical\"). Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein."}],"balance_after":22888051,"source":{"system":"sec-edgar","filing":"0000950103-20-003118","document":"dp121731_4-sumitomo.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1798550/000095010320003118/dp121731_4-sumitomo.xml","form_type":"4"}},{"id":3256738,"issuer":{"id":140739,"kind":"organization","name":"Urovant Sciences Ltd.","symbol":"UROV"},"owners":[{"id":111914,"kind":"organization","name":"Sumitomo Chemical Co., Ltd.","position":1,"cik":"0001798550","reported_name":"Sumitomo Chemical Co., Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Footnote (1)"}},{"id":111915,"kind":"organization","name":"Sumitomo Pharma Co., Ltd.","position":2,"cik":"0001446601","reported_name":"Dainippon Sumitomo Pharma Co Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Footnote (1)"}},{"id":115694,"kind":"organization","name":"Sumitovant Biopharma Ltd.","position":3,"cik":"0001798244","reported_name":"Sumitovant Biopharma Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-02-21T22:54:35.000Z","date":"2020-02-19","kind":"purchase","acquired":true,"shares":12873,"price":13.08,"value":168378.84,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Sumitovant Biopharma Ltd. (\"Sumitovant\") directly owns 22,963,263 shares of Common Stock. Sumitovant is a wholly-owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd. (\"Sumitomo Dainippon\"), which is a 51.76% owned subsidiary of Sumitomo Chemical Co., Ltd. (\"Sumitomo Chemical\"). Sumitomo Dainippon and Sumitomo Chemical may be deemed to indirectly beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) the reported securities that Sumitovant owns. Each of Sumitomo Dainippon and Sumitomo Chemical disclaims beneficial ownership of such reported securities except to the extent of their pecuniary interest therein."}],"balance_after":22872886,"source":{"system":"sec-edgar","filing":"0000950103-20-003118","document":"dp121731_4-sumitomo.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1798550/000095010320003118/dp121731_4-sumitomo.xml","form_type":"4"}}]}